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Insulin is secreted from islets of Langerhans to control glucose homeostasis. 
Deficient insulin secretion is a hallmark of type 2 diabetes. New tools for studying insulin 
secretion are of interest to better understand this process. An advanced method for 
measuring insulin secretion is based on using electrophoresis. In the method, a single 
islet is incubated on a microfluidic device or “chip”. Fluid around the islet is sampled by 
electroosmotic flow and reagents for a competitive immunoassay added to the sample 
stream. The resulting stream is analyzed at 5-10 s intervals by using electrophoresis to 
separate antibody bound and free insulin. In this work, this system was improved by 
adding more automated control of the islet environment, adapting to measure other 
peptides, and performing co-culture experiments to elucidate how adipocytes affect 
insulin secretion.  
To provide further automation, two computer-controlled syringe pumps were used 
to deliver programmed glucose gradients to the islet. Automatic online calibration to 
improve quantification was also added. The device performed an electrophoresis-based 
competitive immunoassay every 8 s and operated for 24 h, resulting in the completion of 
14,000 assays. It was applied to several insulin secretion studies including an 
investigation of glucose pretreatment on glucose sensitivity. A modification of the chip 
was applied to measure the secretory kinetics of C-peptide. The kinetics were compared 
with insulin and used to validate C-peptide as indicator of insulin secretion. The chip was 
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further modified to enable study of the impact of adipocytes on islet insulin secretion by 
co-culture both cells on the same chip. Adipocytes are fat-storing cells that secrete 
glycerol, non-esterified fatty acids and adipokines. The adipocytes strongly potentiated 
insulin secretion from islets. The effect appeared to be due to multiple chemicals released 
by the adipocytes illustrating the potential for observing complex interactions. 
A second microfluidic chip was developed to perform intracellular [Ca2+] 
measurements. The chip was used to investigate the role of X-Box Binding Protein 1 in 
insulin regulated pancreatic α-cell function. The results suggested that [Ca2+] alterations 
did not underlie the dysregulation of glucagon secretion in XBP1 deficient α-cells. 
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Introduction 
 The development of microfluidic devices has led to enhanced capability to study 
cell physiology. Microfluidic systems have been developed with sophisticated cell 
culture capability and on-line chemical analysis of cells based on advances in perfusion, 
surface chemistry, 3D-structure, and analytical instrument integration. This dissertation 
describes the development and applications of microfluidic systems to monitor hormone 
secretion from and intracellular Ca2+ concentration in living cells, such as pancreas β-
cells and α-cells. Important developments include automatic control of perfusate, 24 h 
long-term on chip culture and chemical monitoring, and co-culture for cell-cell interaction 
studies. The goal of the research is to provide more insight into the mechanism of 
insulin secretion to aid in the understanding diseases such as diabetes mellitus and 
obesity. 
Microfluidics and Micro Total Analysis System 
Microfluidics encompasses microfabricated devices or systems utilizing small 
amount of fluids and have channels or chamber structures in the dimension from tens to 
hundreds of micrometers. The first microfluidic system was a miniature gas 
chromatographic analysis system1, including an injecting valve and a 1.5 m long 
separation column on a single silicon wafer and a separately fabricated thermal 
conductivity detector clamped on the column wafer. This system received little interest 
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from the scientific community at that time. A microfabricated capillary electrophoresis 
(CE) device2 developed in 1992 drew more attention to microfluidics and fueled 
explosive developments over the past 2-3 decades leading to the concepts of “micro 
total analysis systems (µTAS)” and “lab on a chip”.3 One goal of µTAS is to incorporate 
one or several analytical features-including sampling, sample preparation and pre-
treatment, separations or extractions, chemical reactions, detection, and data analysis 
onto the same device as an integrated miniaturized system to enable routine complex 
analysis such as clinical diagnostics (see reference 4 and 5 for reviews). 
Comparing to conventional bulk scale or bench-top scale instruments, µTAS has 
many potential advantages, primarily due to the size effect. µTAS requires less bench-
top space and reagent consumption, which saves cost on reagent purchasing, storage 
and disposal. Smaller size increases the feasibility to design portable devices, which 
has the potential to totally change the process of field testing and monitoring (having 
potable systems in individual fields for in situ or online monitoring can greatly increase 
efficiency, compared to sending samples to one or a few labs and waiting for the results 
to make decisions). It also allows less mass and heat transfer distance, mixing and 
reaction time with precise control of small amounts of fluids. Additionally, the ability to 
automate many analytical steps and be multiplexed with well designed and fabricated 
patterns allow increased throughput, reproducibility and cost savings. 
Despite numerous advantages, implementing µTAS also has drawbacks. µTAS 
usually require special and extremely cautious operation and maintenance, because 
they are prone to clogging, contamination and fouling. Issues that are not remarkable in 
macroscale systems such as gas bubbles, leakage or entering of small particles can 
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render microfluidic devices unusable. In practical terms, the small scale also brings 
more challenge to identify and diagnose failures (almost always require assistance of a 
microscope) and trouble-shoot (depending on the severity and location, some issues 
like clogging or contamination can be difficult to resolve). Coupling macroscale 
elements with µTAS for sample and reagent introduction, or coupling large scale or 
commercial detectors can also be challenging. Lastly, microfabrication usually requires 
a clean room and specialized equipment, which can be expensive to access or 
maintain. 
Microfluidics for Cell Studies 
Traditionally, cell culture is performed in bulk using petri dishes or flasks. 
Although useful, they usually fail to reconstitute realistic volume-to-cell ratio and lack 
fluid dynamics and mass transport, both are important features in mimicking in vivo 
environment. They also do not lend themselves to dynamic control over the cellular 
environment or integration with chemical measurements. Microfluidics is an excellent 
candidate for cell studies because the size dimension is compatible with cell sizes and 
microfluidic channels can mimic the vascular capillaries, providing dynamic nutrient 
supply, waste removal and drug presentation or other stimulus administration. Other 
crucial parameters around cells such as the ambient temperature and gas content can 
also be precisely controlled. The small dimension also enables small amounts of tissue 
and media consumption, implementation of high-throughput experiments, and 
integration with detection techniques for chemical monitoring. 
Many applications of microfluidic cell culture have been reported (see reference 6 
and 7 for reviews). One area for use of microfluidics that has emerged is to create in 
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vitro conditions that better mimic an in vivo environment with multiple cell types. These 
tools are often called “organs-on-a-chip” or “human-on-a-chip” to emphasize the 
creation of an in vivo like environment in the controlled confines of a microfluidic device. 
These systems were first developed to mimic in vivo pharmacokinetics and 
pharmacodynamics (PK/PD) on a chip.8–10 The devices have interconnected 
compartments containing lung, liver, fat and other tissues in a circulatory system so that 
drugs introduced to the cells are metabolized like in vivo. Subsequent improvements 
include creation of 3-dimensional environments and long-term culture.11–14 The concept 
has grown beyond drug metabolism so that now microfluidics has been further used for 
other types of cell-cell interaction such as studies on the adhesion of platelets to 
endothelial tissue15 and neovascularlization16. In these “organ-on-chip” studies, the 
experimental output was typically a microscopic inspection of the cells. For the drug 
metabolism studies, the resulting metabolites were measured by collecting products and 
analyzing resulting samples off-line. 
Microfluidics also enables integration of cellular manipulation and cellular 
analysis. One approach has been to combine flow cytometry17,18, cell sorting19,20 and 
cell lysis followed by extraction of intracellular contents21,22 and in vitro cellular 
measurements (see reference 23 for a review of recent developments). More relevant to 
the work in this dissertation, previous work by the Kennedy group demonstrated the 
potential of monitoring the dynamics of hormone secretion with high temporal resolution 
by microfluidics combined with an on-line electrophoretic immunoassay.24 
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Microfluidic Capillary Electrophoresis Immunoassay 
 In this work, extensive use is made of a microchip based immunoassay to 
monitor insulin secretion. Radioimmunoassays (RIA)25 or enzyme-linked 
immunosorbent assays (ELISA)26 are common methods for hormone detection such as 
insulin. Immunoassays can be classified as non-competitive or competitive. Non-
competitive assays rely on the binding of excess amount of radioactively or 
fluorescently labeled antibody (Ab*) to the antigen (Ag) of interest; competitive assays 
encompass unlabeled antibody (Ab), the target antigen (Ag) and a labeled analog of the 
antigen (Ag*) where the two forms of antigen compete for binding sites on antibody. 
Determination of the distribution of bound and free species containing a labeled 
component (detectable) is applied for quantification, where separation of bound and free 
species is essential. 
Non-competitive: Ab* + Ag ↔ Ab* : Ag 
Competitive: Ab + Ag + Ag* ↔ Ab:Ag + Ab:Ag* 
The Kennedy group previously developed a capillary system for monitoring of 
insulin secretion using an on-line capillary electrophoresis (CE) competitive 
immunoassay based on rapid separation of free Ag* and Ab:Ag* complex.24,27 It was 
later implemented on a microfluidic device.28,29 The microfluidic device demonstrated 
the potential of monitoring the dynamics of insulin secretion from single islets of 
Langerhans with up to 8 s temporal resolution by perfusing cells and analyzing the 
perfusate using rapid, on-line electrophoretic immunoassay. 
Compared to the capillary system, the microchip device demonstrated several 
advantages. Cell loading was much easier, and the transparent glass base and open 
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top design allowed morphological monitoring to assess islet health and other monitoring 
such as cellular fluorescence measurements or implanted electrodes. It can be easily 
implemented to allow high throughput measurements and such devices have been 
developed.30,31 The high-throughput device31 was capable of generating more than 
3,600 immunoassays in 40 min and can be applied to compare multiple cells (e.g. 
healthy and diseased cells) in real time and generate much useful information. Another 
direction of cellular studies is to extend the monitoring period to generate more complex 
information to study cellular functions. A significant source of instability of CE hampering 
such application is the buffer, which may become depleted and degraded over several 
hours. Periodically replenishing electrophoresis buffer is one approach to solve that, but 
can be labor-intensive and not automatable on the capillary system or any other 
conventional system. However, several perfusion channels can be easily fabricated on 
a microchip and continuously perfused with fresh buffer, thus allow long-term stability.32 
The original microfluidic chip with cell perfusion, high throughput chip and long-term 
chip are illustrated in Figure 1.1. 
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Figure 1.1. Microchip electrophoresis developed for insulin monitoring. (A) 
Fluidic layouts of the single islet perfusion chip. (B) The side view of the islet 
culture portion. (C) The 15-islet parallel CE chip and (D) long-term chip. In chip 
layouts, black lines represent channels; circles and squares indicate reservoirs. 
Reproduced from References 29,31 and 32. 
 In this dissertation, several developments based on the previous work to allow 
better glucose or other stimulus control, automated long-term monitoring and calibration, 
intracellular [Ca2+] imaging, C-peptide monitoring, and cell-cell interaction studies are 
completed. 
Diabetes Background 
This work focuses on analyzing islet cell function. A justification for studying islets 
is the role of these cells in diabetes. The growing prevalence of diabetes has drawn a 
lot of research interest. From 1980 through 2014, the number of Americans with 
diagnosed diabetes has increased fourfold.33 In 2012, approximately 29.1 million 
Americans, or 9.3% of the population, had diabetes and 86 million American age 20 and 
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older had prediabetes, a condition when fasting blood glucose level is not high enough 
for a diagnosis of diabetes, but enough to increase the risk of type 2 diabetes, heart 
disease, and stroke.34 Diabetes was mentioned as a cause of death in more than 
234,000 cases in 2010 (it is very likely underreported since many people with diabetes 
who died did not have diabetes listed as cause of death), making it the seventh leading 
cause of death. The total cost of diagnosed diabetes in the United States was $245 
billion in 2012, including direct medical costs and reduced productivity. 
The two main types of diabetes are type 1 and type 2 diabetes.35 Type 1 
diabetes, also called insulin-dependent diabetes, happens when β-cells are destroyed 
by autoimmunity leading to a deficiency of insulin. Type 2, or non-insulin dependent 
diabetes, usually starts from insulin resistance of adipose, muscle, and liver tissues, 
when they do not use insulin efficiently, which leads to more insulin secretion from 
pancreas to keep up with the added demand. Meanwhile, gradually declined β-cell 
function-as a hallmark of type 2 diabetes-begins as early as 12 years before diagnosis. 
Development of type 2 diabetes results from the failure of the β-cells to adequately 
compensate for insulin resistance.36 Type 2 diabetes accounts for 90-95% of diabetes 
cases in the US, though the pathogenesis of type 2 diabetes is not well-understood. 
Factors like genetic predisposition and obesity are implicated in the development of 
T2D. 
Islets and Glucose-Stimulated Insulin Secretion 
In our work, we focus on tools to better study insulin secretion from the islets of 
Langerhans since defects in this process are a hallmark of type 2 diabetes.37,38 Islets 
are 75-200 µm diameter spheroid cell clusters located in the pancreas that contains 
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2000-4000 cells each. An adult human pancreas has approximately 1 million islets, 
comprising 1-2 % of the volume of the pancreas. Figure 1.2 depicts a typical mouse 
islet (left) and an image of several isolated mouse islets (right)39. 
	 	 	
Figure 1.2. Images of islets of Langerhans. (A) A single islet with insulin (green), 
glucagon (red) and nuclei (blue) labeled (Image credit: “Mouse islet LM Solimena 
Lab” by Chistin Süß, Jakob Suckale, Michele Solimena). (B) A photomicrograph 
image of several isolated islets. 
Islets are composed of five cell types: α-cells (~20 %) secrete glucagon; β-cells 
(~70-80 %) secrete insulin; delta-cells (<10 %) secrete somatostatin; PP-cells (<5%) 
secrete Pancreatic Polypeptide; a small amount of epsilon-cells (<1 %), which were 
found more recently, secrete ghrelin.40 
Insulin is secreted from β-cells at elevated blood glucose concentration, and then 
carried by the bloodstream throughout the body. Released insulin is crucial for 
maintaining glucose homeostasis.41 Insulin secretion is stimulated by glucose, with both 
triggering and amplifying effects. The triggering pathway is initiated when glucose is 
rapidly transported into the β-cells via GLUT2 and metabolized by oxidative glycolysis to 
produce ATP. The rise in ATP/ADP leads to the closure of ATP-sensitive K+ (KATP) 
channels, membrane depolarization, opening of voltage-operated Ca2+ channels 
100 µm	A B 
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allowing Ca2+ to enter the cell. The rise in cytoplasmic free Ca2+ concentration then 
leads to subsequent triggering of insulin secretion via exocytosis.41 
The amplifying pathway is more complex. As suggested by previous studies, it is 
independent of KATP channels (it is also referred as KATP channel independent insulin 
secretion in some reports) yet relies on glucose metabolism.42,43 Low concentrations of 
glucose (1-6 mM) can influence insulin secretion by the amplifying pathway, but it 
normally remains silent if [Ca2+]i has not been raised first by the triggering pathway.41 
Figure 1.3 illustrates a schematic representation of the triggering and amplifying 
pathways.41  
	
Figure 1.3.	Simplified schematic of the triggering and amplifying pathways of 
GSIS (+, stimulation; -, inhibition). Triggering pathway happens when glucose 
enters the cell and subsequent metabolism results in an increase in ATP, which 
causes the KATP channels to open. The resulting membrane depolarization causes 
the voltage-sensitive Ca2+ to open and ultimately results in exocytosis of insulin. 
Several drugs affecting KATP and Ca2+ channels are illustrated. Amplifying 
pathway is independent of KATP channels and relies more on metabolism of 
glucose. Reproduced from reference 41. 
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Insulin Secretion Dynamics 
Insulin secretion has complex dynamics including a biphasic and pulsatile 
pattern.44 The 1st phase consists of a sharp burst in insulin secretion that typically 
occurs within 2-5 min of glucose stimulation (typically presented as a step from 3 mM to 
11 mM). The 2nd phase is characterized by a gradual rise in insulin release that is 
sustained for several minutes and is often pulsatile. The lengths and profile of the 2nd 
phase varies from species to species. For example, in rodent models, rats and humans 
usually have stronger 2nd phase insulin secretion than mice.45 
	
Figure 1.4. Biphasic and pulsatile insulin secretion. Glucose causes a 1st phase 
spike of insulin secretion followed by a 2nd phase of insulin secretion. The 2nd 
phase usually gradually rise and is often pulsatile. Reproduced from reference 46. 
In vivo insulin secretion has a 5-15 min oscillation period.47,48 Several studies 
suggest the oscillatory secretion patterns are important for optimal insulin action49–51 
and insulin secretion52–54. Loss of such oscillatory patterns is implicated in the 
development of type 2 diabetes51,55–58, and may be one early sign of type 2 diabetes in 
relatives of type 2 diabetics or obese non-diabetics59,60. A comparison demonstrating 
the oscillations in healthy and diabetic individuals is illustrated in Figure 1.5. A period of 
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10 min insulin secretion and well contained glucose level were observed in healthy 
individuals and irregular insulin secretion and elevated glucose level were found in 
diabetics. 
	
Figure 1.5. Plasma glucose and serum insulin level in normal (A) and diabetic 
subjects (B) when infused with 6 mg kg-1 glucose for 1 min every 10 min. The 
diabetic subjects exhibited irregular insulin secretion and elevated glucose level. 
Reprinted from reference 37. 
Long-term Oscillatory Patterns of Insulin Secretion 
In additional to the short-term trends, some studies also suggest longer period of 
insulin secretion with frequency of 50-120 min, termed as ultradian rhythm61 or even 
longer than a few hours, termed as a circadian rhythm62–64. Alterations in the ultradian 
rhythms have been reported in patients with type 2 diabetes.65–67 
	
Figure 1.6. Insulin secretion rate (ISR) profiles from a control (A) and a type 2 
diabetic patient (B) during continuous enteral nutrition. The ISR pulses in the 
diabetic subject were significantly less defined and lower in amplitude than the 







Gradual Glucose Control and Glucose Sensitivity Studies 
In vitro studies of glucose stimulated insulin secretion traditionally use a step 
change from low to high glucose (e.g., 3 to 11 mM or 3 to 17 mM). However, in vivo 
blood glucose changes in mammals have patterns of gradual rises and falls. Figure 1.7 
illustrates such gradual glucose change in humans68 and rodents69. Despite the success 
of using step changes in glucose to study insulin secretion, it fails to mimic in vivo 
physiological glucose dynamics. A system that allows islets to be exposed to controlled 
gradients of glucose would greatly expand the capabilities of in vitro studies. 
	
Figure 1.7. Blood glucose profile of human (A) and mouse (B). In human glucose 
level rises after meals and falls after a few hours, while it is more irregular in 






One application where precise control of the glucose concentration gradient is 
used is to measure β-cell glucose sensitivity, defined by the threshold glucose level 
where β-cells start to secret insulin. β-cells normally secrete insulin when plasma 
glucose exceeds 7 mM; however, they will respond to increasing insulin demand, such 
as during hyperglycaemia, by increasing their mass, secretory function, and glucose 
sensitivity.70,71 Ultimately β-cells’ capacity to adapt to glucose response and expand 
mass may be disrupted and lead to the onset of type 2 diabetes.59,72,73 A previous 
study74 demonstrated that after undergoing 90% pancreatectomy, the remaining rat 
islets became more sensitive to glucose, apparently to compensate for the loss. It has 
been known that β-cell mass compensation is usually slow to respond effectively to 
decreased insulin sensitivity.75,76 Increase of β-cell glucose sensitivity or 
metabolic/hormonal amplification of secretion are two candidates of hypothesized faster 
functional compensation. In this dissertation, a collaborative effort has been placed on 
investigating the hypothesis that chronic glucose causes rapid functional compensation 
and shifts islet glucose sensitivity. 
	
Figure 1.8. Using glucose ramp to measure glucose sensitivity. Control (A) and 
Foxa1/a2 mutant (B) islets were perfused by a glucose ramp (0-50 mM) flowing at a 
rate of 1.25 mM/min, followed by 20 min Krebs buffer wash and 30 mM KCl 
stimulation as positive control. Control islets produced a rapid and sharp 1st phase 
insulin secretion between 5-10 mM, while mutant islets were elicited by 3.75 mM 
glucose, failed to produce a distinct peak, and had more total insulin output. 





Glucose ramp has been proved useful to measure in vitro glucose sensitivity.77 
As illustrated in Figure 1.8, islets were exposed to a glucose ramp (0-50 mM, 1.25 
mM/min) and insulin secretion was sampled every few minutes. Left or right shift of the 
threshold glucose level, the existence of distinct first phase insulin peak, and total 
insulin output are key parameters used to assess glucose sensitivity. Microfluidics offers 
the opportunity to perform such experiments with better secretory monitoring and more 
efficient use of islets. 
Methods for Islet Function Characterization 
Several cellular parameters have been used to characterize islet function, 
particularly focused on pancreas β-cells and α-cells. This dissertation is focused on 
several analytical methods developed to measure insulin, C-peptide and intracellular 
[Ca2+]. 
1) Insulin detection 
 Insulin is the most commonly studied pancreatic hormone and widely used for β-
cell functions characterization, as illustrated in several examples discussed above. 
Insulin secretion patterns have been investigated in vivo78, in perfused pancreas79, and 
with isolated islets46. In vitro experiments help elucidate insulin secretion mechanisms 
with simplified biological system compared to in vivo. Furthermore, to observe the fast 
oscillatory (2-5 min) dynamics, single isolated islets experiments are usually required to 
prevent destructive interference of out of phase oscillations from multiple islets in a 
large batch80; high temporal resolution sampling is also required. A comparison between 
a perfused pancreas and isolated islets is illustrated in Figure 1.9. Only the biphasic 
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nature of insulin secretion is observed with the perfused pancreas while the 2nd phase 
oscillatory dynamics are observed with single islet. 
	 	
Figure 1.9. Insulin release from a perfused pancreas (A) and a perfused single islet 
(B). Much more oscillatory dynamics are observed from the single islet while only 
the biphasic nature of insulin release from the perfused pancreas is observed. 
Adapted  from reference 81 and reproduced from reference 46. 
Immunoassay has remained the primary and classical method for assaying 
hormone release with high sensitivity. Either in vivo or in vitro experiment involves blood 
drawing or fraction collection for offline immunoassay measurements, which are highly 
labor and time intensive. Another disadvantage of offline monitoring is temporal 
resolution, which is usually on the order of minutes. Increasing the frequency of fraction 
sampling is one way to compensate it, but would bring extreme increase of time and 
labor. 
	 As illustrated in previous section, microfluidic capillary electrophoresis 
immunoassay is a good candidate for automatic and high temporally resolved insulin 
monitoring. In this dissertation, we demonstrate a microfluidic device which we 





concentration (or that of any drug) applied to the cells and by incorporating a method for 
automated calibration at defined times. For the control of glucose, the system 
incorporates two independent syringe pumps loaded with low and high concentration 
glucose. Flow rates of both are controlled by a home-made LabView program. By 
mixing 2 syringe pumps’ contents at different flow rates through a tee fabricated on the 
electrophoresis chip, arbitrary glucose gradients can be generated. 
Insulin secreted from the islets is measured at 5-10 s intervals by an 
electrophoretic competitive immunoassay. Single islets are perfused with different 
concentration of glucose. Processes of sampling of insulin secreted by the islet, insulin 
and FITC-insulin mixing and their competitively reacting with insulin antibody are 
achieved by electroosmotic flow (EOF). A high-voltage relay controls continuous 
injection of the sample plug to the separation channel, where free FITC-insulin and 
FITC-insulin bound to antibody are separated. The integrated system can perform 
14,000 electrophoresis assays in 24 h and automatically control culture conditions, thus 
allowing continuous monitoring of insulin under well-controlled conditions. 
2) C-peptide detection 
C-peptide is a short 31-amino-acid peptide connecting insulin’s A-chain and B-
chain in proinsulin, which is subsequently removed from the A-chain and B-chain to 
produce mature insulin. A diagram of preproinsulin process is illustrated in Figure 1.10. 
1:1 mole of C-peptide and insulin are then stored in secretory granules of the β-cells 
and both are released eventually. An alternative way to indirectly measure insulin 
secretion is to measure C-peptide levels.82 
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Moreover, visual assessment of pancreatic insulin content would be a useful 
approach to study the loss of β-cell insulin content, which can be a possible cause of 
pancreatic exhaustion.83 However, imaging of insulin in the living animal or humans has 
not yet been achieved. A human proinsulin with C-peptide-bearing Superfolder Green 
Fluorescent Protein (CpepSfGFP) has been expressed in transgenic mice and the goal 
is to use it as a dynamic reporter of insulin storage and secretion in situ. Although in 
vivo fluorescence imaging of the pancreatic surface allowing assessment of pancreatic 
islet insulin content is important and the ultimate goal of this method, it is also 
necessary to validate that the kinetics of the release of insulin and CpepSfGFP are 
identical. In vitro measurement using isolated single islets is a good approach to 
compare CpepSfGFP and insulin release. In this dissertation, we developed a 
microfluidic device to monitor CpepSfGFP secretion from isolated single islets and 
compared the resulting secretion pattern with insulin. 
	
Figure 1.10. Preproinsulin Process. The signal peptide sequence is removed from 
the N-terminus of preproinsulin by proteases, forming proinsulin with 3 disulphide 
bonds. Further proteolytic cleavage removes the C-peptide producing insulin. 
Reproduced from reference 84. 
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3) Intracellular [Ca2+] Imaging 
Ca2+ influx has been known as the trigger of exocytosis of hormones including 
insulin and glucagon. Fluorescence imaging is a promising and widely used technique 
for studying living cells. Intracellular [Ca2+] measurements were revolutionized after the 
advent of cell-permeant Fura-2, a Ca2+ sensitive fluorescent dye.85 Its excitation 
wavelength shifts from 380 nm to 340 nm upon Ca2+ binding, and the ratio of the 
integrated intensities of the fluorescence emission at 510 nm from 340 and 380 nm 
excitation allows for quantitation of intracellular Ca2+ following calibration. 
Conventional Ca2+ measurements are usually performed with cell affixed on a 
coverslip, sealed into a chamber with approximately 3 mL volume. The chamber is 
perfused with a peristaltic pump. Although it has been applied in many applications, the 
drawbacks include large volume of media consumed and difficulty in precisely 
controlling the cell culture environment. The instrumentation itself includes several parts 
which are relatively hard and expensive to maintain. The microfluidic chip for Ca2+ 
imaging may allow rapid and precise introduction of fresh media to the cells. Several 
microfluidic devices have been implemented for intracellular Ca2+ imaging recently.86–88 
Our research group also have developed microfluidic devices for Ca2+ imaging in 
pancreas islets.89 
In this dissertation, a PDMS/glass hybrid microfluidic device for Ca2+ imaging 
studies was developed. This device can accommodate a 5 mm × 5 mm square 
coverslip-where the cells are attached to, and continuously perfused during 
measurements. Excess buffer is removed from the top of the cell chamber and the 
temperature is well controlled. 
	 20	
The device was applied to study the role of X-box binding protein 1 (XBP1) in 
insulin regulation of pancreas α-cell function. Endoplasmic reticulum (ER) stress has 
been suggested to contribute to reduced β-cell mass90,91, but its role in α-cell biology is 
less known. XBP1 is a transcription factor that plays a critical role in mediating the 
unfolded protein response (UPR), which is an important process towards ER stress. 
Recent study suggested that β-cell specific XBP1-deficient mice exhibit β-cell 
dysfunction.92 
Hyperglucagonemia caused by α-cell dysfunction is a feature of type 2 diabetes, 
but the mechanism contributing to this hypersecretion is not fully understood. In addition 
to glucose93, it has been suggested insulin signaling in α-cells is critical to the regulation 
of glucagon secretion94,95. To investigate the role of XBP1 in α-cells, in vivo and in vitro 
models were created by a collaborating lab. In our work, stable XBP1 knockdown and 
overexpression α-cell lines’ intracellular Ca2+ were measured and compared with the 
control groups. The data we collected help explain the mechanism of XBP1 deficiency 
in altered insulin signaling and glucagon secretory dysfunction. 
Obesity and Adipocytes Background 
Obesity 
In this work, we used microfluidics to investigate how adipocytes alters islet 
function. This work was motivated by the connections between obesity and type 2 
diabetes. Obesity is a growing epidemic in the United States. As of 2014, more than 
one-third (34.9% or 78.6 million) of US adults were obese. Not a single US state had a 
prevalence of obesity less than 20%.96 Obesity is a medical condition when excess 
body fat has accumulated to the extent that may have a negative effect on health, and is 
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usually accessed by measuring body mass index (BMI, mass height-2). BMI values 
between 19-25 kg m-2 are normal, 25-30 are overweight, and >30 are considered 
obese. Obesity is related to conditions include heart disease, stroke, type 2 diabetes 
and certain types of cancer. The estimated annual cost of obesity in the US was $147 
billion in 2008. 
Obesity is characterized by an increased mass of adipose tissue both in the 
number and size of adipocytes, occurs when the intake of food exceeds the energy 
need of the body for a sustained period of time.97  Blood fatty acid levels tend to be 
elevated in obese individuals. Short-term treatment of β-cell with fatty acids stimulates 
insulin secretion, while chronic fatty acid impairs insulin secretion.98,99 Adipocytes also 
secrete other hormones which have been proven affecting β-cell function and 
survival.99–101 Understanding the endocrine and metabolic interactions between 
adipocytes and islets would be essential to help us better understand the link between 
obesity and impaired insulin secretion in type 2 diabetes. 
Adipocytes 
 Adipocytes are the cells that primarily compose adipose tissue, specialized in 
storing energy as fat. They play a key role in energy metabolism within an organism and 
are at the center of obesity and type 2 diabetes research, making it important to 
understand the physiology of adipocytes. 
Typically, white adipose tissue is found subcutaneously in the abdominal region 
and skeletal muscle. The vast majority of stored energy in the body is in the form of 
triglycerides (TG)-comprised of one moiety of glycerol and three of fatty acids, which 
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account for ~95% of adipose tissue volume.102,103 Triglycerides are converted into 
individual moieties of one glycerol and three fatty acids through lipolysis.103  
Non-esterified fatty acids (NEFAs) are oxidized to provide a fuel source in 
hypoglycemic states, such as in fasting or starvation. NEFAs can also activate insulin 
secretion.102,104 But it has been demonstrated that plasma NEFA concentrations are 
elevated in obese individuals103,105 and have harmful effects on peripheral tissues106–108. 
Elevated NEFAs concentration have been implicated contributing to the development of 
impairment of insulin response in peripheral tissues such as muscle and liver which may 
lead to insulin resistance, and they also have been implicated in the development of β-
cell dysfunction. 
NEFAs have been shown to have bimodal effects on insulin secretion so that 
short term they enhance secretion109 but with chronic exposure suppresses insulin 
secretion108, suggesting a possible mechanism for dysfunctional insulin secretion in 
diabetes. It was reported that insulin secretion enhanced 65 fold after acute exposure to 
0.5 mM stearate.109 As of the chronic treatment, it is worth mentioning that previous 
work suggested that fatty-acid induced impairment of GSIS does not occur unless the 
islets are cultured with >8 mM glucose. This phenomenon is termed as 
glucolipotoxicity.100,110 
Besides NEFAs, adipocytes also produce adipokines (a group of hormones and 
cytokines) which have been shown to affect pancreatic β-cell function and survival.100,101 
These molecules have been found affecting glucose stimulated insulin secretion, insulin 
sensitivity and β-cell apoptosis and proliferation. For example, leptin inhibits insulin 
secretion111 and protects β-cells from apoptosis112. Adiponectin increases insulin 
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secretion113, insulin sensitivity114 and β-cell proliferation115, and low levels of adiponectin 
were found in obesity and type 2 diabetes. Other molecules and proteins, including 
tumour necrosis factor α (TNFα), resistin, dipeptidyl peptidase IV (DPP-IV) and apelin, 
also have been found affecting β-cell and their functions are reviewed in reference 101 
and 116.  A summary of the main adipokines with demonstrated effects is given in 
Table 1. 
Table 1. Summary of adipokines with demonstrated effects on pancreatic β-cells. 
Reproduced from reference 101. 
 
Even though many adipokines have substantial effects β-cells as illustrated 
above, most of the reported studies have been done using individual adipokines applied 
in isolation. To implement models that mimic the in vivo case, where the β-cells are 
exposed to a full range of adipokines would provide a more integrated perspective to 
study their effects. One study115 investigated the interactions between adiponectin and 
leptin and suggested that the ratio of adiponectin to leptin may possibly be a significant 
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factor to assess the overall effects. Actually, it is known that many adipokines act used 
by the pathways that intersect-including many signaling pathways and insulin receptor 
itself. Meanwhile, the reported changes in circulating adipokine concentrations observed 
in metabolic diseases (see reference 117 for a review) are complex and many questions 
are still unanswered. Further studies that focus on the effects of combinations of 
adipokines are needed. 
One approach to study the complex effects is to co-culture adipocytes and β-cells 
to provide an integrated profile of adipokines to stimulate the islets. This field is 
understudied, although existing work suggests that adipocytes induce dysfunction in β-
cell118 and molecules like α-lipoic acid protect β-cells119. In this dissertation, we 
demonstrate with a microfluidic system that adipocytes impact insulin secretion that 
cannot be explained by the NEFA results alone. The results show that better mimicking 
the in vivo microenvironment, where the β-cell is exposed to full range of adipokines, 
provides a new perspective to study adipokines’ effects on the β-cell different from the 
previous studies with individual adipokines. 
The murine 3T3-L1 cell line is a model system for adipocytes. The work 
presented in this dissertation used cultured 3T3-L1 adipocytes. Preadipocytes can be 
differentiated into adipocyte-like cells that accumulate lipids120, and it has been 
extensively studied and well-characterized.121–123 Although some differences exist 
between cultured cells and primary adipocytes from animals (e.g. secreted leptin 
levels124), use of cell line allows long term culture while isolated adipocytes are only 
viable for a short time (< 24 h) after isolation. Ear mesenchymal stem cells (EMSCs) 
can be differentiated into a variety of cell types including adipocytes.125–128 Although 
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they are still being characterized, they have the potential to be used to derive 
adipocytes in the future. 
Dissertation Overview 
 Overall, the objective of this research was to design and develop novel analytical 
techniques to study insulin secretion from islets of Langerhans. The design, 
development, and characterization of a microfluidic device combining automatic glucose 
(or other stimulus) gradient control and calibration for monitoring insulin secretion from 
single islets for 24 h is presented in Chapter 2. It was used to study insulin secretion 
dynamics from islets for 24 h with a temporal resolution of 8 s. This work was published 
in Methods in Molecular Biology. The automatic glucose gradient control allowed 
studies of glucose sensitivity, and the data and results were published in Endocrinology 
in collaboration with Dr. Leslie Satin of the Brehm Diabetes Center at the University of 
Michigan Medical School. 
 The microfluidic device was further developed to a microchip electrophoresis 
device capable of co-culture two cell types and chemical monitoring. The data and 
results were illustrated in Chapter 3. We were able to study the effects of adipocytes on 
islets’ insulin secretion and found augmented insulin secretion after short-term 
treatment. Data and results from Chapter 3 are in preparation for submission. 
 Chapter 4 presents a microchip electrophoresis device to monitor low 
concentration fluorescent labeled peptides. It was applied to measure the secretion 
kinetics of C-peptide-bearing Superfolder Green Fluorescent Protein (CpepSfGFP) from 
single islets, and compared with insulin secretion, to validate the capability of using 
CpepSfGFP imaging to measure insulin function in vivo. Results in Chapter 4 were 
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published in Diabetes in collaboration with Dr. Peter Arvan of the Brehm Diabetes 
Center at the University of Michigan Medical School. 
 A PDMS/glass hybrid microchip was developed for intracellular [Ca2+] imaging 
with cell lines, allowing convenient fabrication, cell manipulation and chip operation. It 
was applied to study the role of X-Box Binding Protein 1 in insulin regulated pancreatic 
α-cell function. The intracellular Ca2+ concentration data were published in Diabetes in 
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Microchip Electrophoresis Devices for Chemical Gradient Generation and 24 h 
Operation and Application to Perfusion and Chemical Monitoring of Living Cells 
Introduction 
Pancreatic β-cells, accounting for 70-80% of total cells in pancreatic islets, 
secrete insulin to help maintain glucose homeostasis.1 Glucose stimulated insulin 
secretion involves several sequential cell signaling steps including rise of ATP/ADP ratio 
induced by glucose metabolism, closure of ATP sensitive K+ channels, membrane 
depolarization, and opening of voltage-operated Ca2+ channels that allow Ca2+ to enter. 
The rise in cytoplasmic free Ca2+ concentration leads to subsequent triggering of insulin 
secretion.2 β-cells dysfunction is fundamental to the pathophysiology of type 2 
diabetes.3 
Immunoassays such as RIA and ELISA are the most commonly used method to 
monitor insulin secretion from cells. Although the sensitivity is high, conventional 
immunoassays are usually labor and time intensive, making high temporal resolution 
measurements challenging. Microchip electrophoresis has been demonstrated useful to 
perform online immunoassay4 with high speed, high efficiency and small sample volume 
requirement5. Microfluidics can also be used for cell culture6,7, allowing it to be an 
excellent platform for simultaneous cell culture and chemical monitoring. Applications of 
cell culture combining flow cytometry8,9, cell sorting10,11, cell lysis followed by extraction 
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of intracellular contents12,13 and in vitro cellular measurements (see reference 14 for a 
review of recent developments) have been reported. 
Our research group developed a microchip electrophoresis (MCE) system for cell 
culture and insulin monitoring with competitive immunoassay.15,16 Living islets were 
cultured on the microfluidic chip and continuously perfused.16 Secreted insulin was 
sampled by electroosmotic flow (EOF) and monitored with 6 s temporal resolution by 
repetitive immunoassay using MCE. 
These systems were capable of operating continuously for 2 h; however, at 
longer times the electropherogram signal became unstable and decreased. This effect 
was primarily due to degradation or depletion of buffers. It would be desiable to extend 
the running time of the microfluidic device allowing automated chemical monitoring over 
longer periods of secretion. Such measurements could be used to measure longer term 
trends in insulin secretion such as ultradian17 and circadian rhythm18–20. Alterations in 
the ultradian rhythms have been reported in patients with type 2 diabetes.21–23 Such 
rhythms have been difficult to observe in vitro due the challenge of monitoring islets 
over such long times. 
Several studies have explored performing long term cell culture and analysis with 
microfluidic systems.24–26 Although demonstrated useful for monitoring dynamic cellular 
activities, measurements were performed with relatively low temporal resolution (every 
30 min-1 h) in these works. Our lab previously developed a microfluidic cell culture 
device capable of long-term electrophoresis operation.27 To improve the stability of the 
electrophoresis, buffers were continuously replenished with perfusion channels built into 
the device. The electrophoretic immunoassay performance was calibrated every few 
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hours to measure any drift in calibration over the course of the 24 h monitoring period. 
Although it was the first system to demonstrate stable 24 h electrophoresis operation, it 
still required manual interventions, e.g. to perform calibrations. It would be desirable to 
have a system to automatically check the calibration to approach unattended 
monitoring. 
Meanwhile, in vitro glucose stimulated insulin secretion model is traditionally built 
on direct change from low to high glucose (e.g., 3 to 11 mM or 3 to 17 mM). However, in 
vivo blood glucose change within mammalian animals usually have patterns of gradual 
rise and fall. Despite the success of using step changes in glucose to study insulin 
secretion, it fails to mimic such in vivo glucose dynamics. A system that allows islets to 
be exposed to controlled glucose gradient would greatly expand capabilities of in vitro 
studies. 
In this chapter, we demonstrate a microfluidic device that is improved upon 
previous designs by incorporating a method to automatically generate arbitrary glucose 
(or any drug) profiles applied to the cells and by incorporating a method for automated 
calibration at defined times. For control of glucose, the system incorporates two 
independent syringe pumps loaded with low and high concentration glucose. Flow rates 
of both are controlled by a locally written LabView program. By mixing 2 syringe pumps’ 
contents at different flow rates through a tee fabricated on the electrophoresis chip, 
arbitrary glucose gradients can be generated. 
Insulin secreted from the islets is measured at 5-10 s intervals by an 
electrophoretic competitive immunoassay. Every few hours, a single pole double throw 
(SPDT) relay briefly moves the electrical connection from the islet reservoir to the 
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parallel insulin standard reservoir, allowing the electrophoretic sampling of insulin 
standards while maintaining the islet under perfusion. Single islets are perfused with 
different concentration of glucose. Processes of sampling of insulin secreted by the 
islet, insulin and FITC-insulin mixing and their competitively reacting with insulin 
antibody are achieved by electroosmotic flow (EOF). A high-voltage relay will control 
continuous injection of sample plug to the separation channel, where free FITC-insulin 
and FITC-insulin bound to antibody are separated. The integrated system can perform 
14,000 electrophoresis assays in 24 h and automatically control culture condition, thus 
allowing continuous monitoring of insulin under well-controlled conditions. 
This system is applied to measure glucose sensitivity of islets exposed to various 
glucose concentrations overnight in vitro with gradient glucose profile.28 The 
concentrations of glucose that were able to trigger measureable insulin secretion were 
progressively reduced by 3 mM, 11 mM or 11 mM + Diazoxide (an insulin secretion 
inhibition drug) overnight treatment, suggesting an increase in glucose sensitivity. 
Experimental Section 
Chemicals and reagents 
Cell culture reagents were purchased from Invitrogen (Carlsbad, CA). 
Monoclonal antibody (Ab) to human insulin was purchased from Meridian Life Science 
(Memphis, TN). Tricine, electrophoresis grade was obtained from MP Biomedicals 
(Aurora, OH). Collagenase P was obtained from Roche Diagnostic (Indianapolis, IN). 
Fluorescein isothiocyanate--labeled insulin (FITC-insulin) Tween 20, 
ethylenediaminetetraacetic acid (EDTA), insulin and fatty acid free bovine serum 
albumin (BSA) were obtained from Sigma-Aldrich (St. Louis, MO). All other chemicals 
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were from Fisher (Pittsburgh, PA). All solutions were prepared with Milli-Q (Millipore, 
Bedford, MA) 18 MΩ deionized water and filtered with 0.2 µm nylon syringe filters 
(Fisher) before using. Stock antibody solution was stored at 4 °C in the manufacturer 
provided phosphate buffer saline. Stock FITC-insulin was diluted to 166 µM in 
immunoassay reagent buffer and stored at -20 °C. 
Balance salt solution (BSS) contained 125 mM NaCl, 5.9 mM KCl, 1.2 mM 
MgCl2, 2.4 mM CaCl2, 25 mM Tricine, and 0.7 mg mL-1 BSA. Immunoassay reagent 
buffer contained 60 mM NaCl, 1 mM EDTA, 20 mM tricine, 0.1% (w/v) Tween 20 and 
0.7 mg mL-1 BSA. Electrophoresis buffer was 20 mM NaCl and 150 mM tricine. All 
buffers were adjusted to pH 7.4. 
Microfluidic Chip Fabrication and Preparation 
The microfluidic devices were fabricated using a method previously 
described.15,29 Briefly, 1 mm thick Borofloat photomask blanks (3.8 cm × 7.6 cm) coated 
with a 120 nm layer of chrome and AZ1518 positive photoresist (Telic Company, 
Valencia, CA) are exposed to UV light for 6 s through a patterned photomask (Fineline 
Imaging Inc., Colorado Springs, CO). The exposed photomasks were developed in AZ 
726 MIF developer (Clariant Corp., SummerVille, NJ) and the exposed chrome was 
developed in CEP-200 chrome etchant (Microchrome Technologies, Inc., San Jose, 
CA). The exposed glass was etched in 17:24:79 (v/v/v) HNO3/HF/H2O for 25 min to 
create 25 µm deep channels on the top wafer. Fluidic access holes were drilled with 360 
µm diameter drilling bits (Kyocera Tycom, Costa Mesa, CA). The remaining photoresist 
was removed with acetone and the remaining chrome was removed with the CEP-200 
chrome etchant. Glass wafers were washed for 20 min in piranha solution (3:1, v/v, 
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H2SO4/H2O2) and then heated RCA solution (5:1:1, v/v/v, H2O/NH4/H2O2) for 40 min. 
Caution!: piranha solution is aggressive and explosive. Never mix piranha waste with 
solvents. Check the safety precautions before using it. The wafers were rinsed with 
water, aligned and annealed at 610 °C for 8 h. Reservoirs and access ports (IDEX 
Health and Science, Oak Harbor, WA) were glued to the device over drilled access 
holes with epoxy glue. 
Computational modeling 
Perfusion of the mixing Tee (gradient generator) was modeled using COMSOL 
Muitiphysics (COMSOL, Inc., Burlington, MA). The “laminar flow” and transport of diluted 
species” models were used to monitor the mixing process. All simulations assumed water 
perfusion through the chip, with a density of 998 kg m-3 and a viscosity of 1.002 × 10 -3 
Pa ·s’ (20 °C). The microfluidic channels were modeled in 2D with the shallow channel 
set to 36 µm tall. The sum of the flow rate was set at 0.6 µL min-1, while both arms’ flow 
rates were adjusted accordingly to simulate different mixing conditions. 
Figure 2.1. (Next page) Overview of the microfluidic platform for monitoring insulin 
secretion from single islets. (A) The channel layout of the microfluidic device. 
Microfluidic channels are indicated by solid lines; Electrical connections are 
indicated by dotted lines. Circles indicate perfusion inlets and squares indicate 
reservoirs that are sampled by electroosmotic flow (EOF). Arrows indicate 
directions of perfusion flow. Gradient mixer indicates the Tee fabricated on chip to 
generate arbitrary glucose gradients. The shaded portion is heated at 37°C with a 
thin film heater. The star indicates laser-induced fluorescence occurred 1 cm past 
injection point. -HV are where high voltage is applied. (B) Side-view of an islet 
perfusion chamber. Islet is loaded into a 0.1 μL chamber and perfused with 
pressure-driven flow. After which the fluid flows into a 100 μL fluidic reservoir. Islet 
is loaded into a 0.1 μL chamber and perfused with pressure-driven flow, after which 
the fluid flows into a 100 μL fluidic reservoir. Solution with insulin from the 
chamber is sampled by EOF through the sampling channel at a rate of 
approximately 2 nL min−1. (C) Scheme for perfusing reservoirs. Perfusion buffer 
supply is pushed by syringe pumps or pressurized and fluid flows into the chip to 




Microfluidic Chip Operation 
The layout of the microfluidic chip is shown in Figure 2.1. All solutions were daily 
filtered from a stock solution to prevent introduction of particulates to the chip or 
degradation. Prior to experiments, the chip was conditioned with 0.1 M NaOH through 
the channels, followed by deionized water and then experimental buffers. During chip 
operation, the islet chamber was perfused with fresh BSS buffer pumped by 2 syringe 
pumps through fused-silica capillaries inserted into vials. All the other reservoirs were 
continuously pumped with fresh solutions pressured with 5-30 psi of Helium. During a 
long-term operation, all solutions excessing 100 µL were removed with a capillary 
connected to a vacuum pump to prevent overflow in the reservoirs. A high voltage (HV) 
of -6 kV was applied at the waste reservoir of the device. With all the other reservoirs 
grounded, Solutions containing insulin secreted by islet and 100 nM FITC-insulin are 
mixed and reacted competitively with 50 nM Ab on a heated reaction channel. Both 
FITC-insulin and Ab are dissolved in immunoassay reagent buffer. The electrophoresis 
buffer was placed in the gate and waste reservoirs. A SPDT high voltage relay (Kilovac, 
Santa Barbara, CA) was connected to the gate reservoir. When the gate was opened 
for a short period of time, the gate reservoir was connected to a -5 kV HV and a sample 
plug was allowed to flow into the 1.5 cm separation channel. Separation occurred in this 
channel resulting in a zone of FITC-insulin bound to antibody (B) followed by a zone of 
free FITC-insulin (F). Laser-induced fluorescence (LIF) detection occurred 1 cm from 
the injection cross and the ratio of the peak area of B/Fs were used to quantify insulin 
with calibration. 
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Islets were perfused with BSS and different concentrations of glucose at 0.6 µL 
min-1. For islet experiments, a single islet was placed in the grounded islet reservoir. 
Perfusate from the islet was sampled via electroosmotic flow. For calibration, grounding 
was alternated from the islet reservoir to the insulin standards reservoir, allowing the 
electrophoretic sampling of insulin standards without interfering islets, which was still 
continuously perfused with normal glucose. During long-term experiments, a home-
made LabView program controlled a SPDT relay to switch between islet reservoir and 
insulin standard reservoir to calibrate the immunoassay. 
For control of glucose, the system incorporates two independent syringe pumps 
loaded with low and high concentrations of glucose. Flow rates of both are controlled by 
a home-made LabView program. By mixing 2 syringe pumps’ contents at different flow 
rates through the Tee fabricated on the electrophoresis chip, arbitrary glucose gradients 
can be generated. We used fluorescein to mimic glucose, programmed step change 
(with frequency of 5 min) and ramping change (with frequency of 1 min), and detected it 
at the end of the mixing channel to assess the gradients. 
Instruments and LIF Detection 
LIF detection was performed with a Zeiss Axiovert 35 M inverted microscope 
equipped with a Photon Technology International 814 photometer (Birmingham, NJ). 
The 488 nm Excitation light of a 20 mW optically pumped semiconductor Sapphire laser 
(Coherent, Santa Clara, CA) is directed onto a 500 nm long-pass dichroic mirror and 
through a 40×, 0.6 numerical aperture, long working distance objective (Carl Zeiss, Inc., 
Thornwood, NY). After passing through the dichroic mirror, the emission light is further 
filtered through a 530 ± 30 nm band-pass filter. The fluorescence emission is further 
	 42	
spatially filtered by an iris diaphragm on the photometer. Instrument control and data 
collection are performed using LabVIEW software written in house (National 
Instruments, Austin, TX). High-throughput analysis of collected electropherograms is 
performed using Cutter software.30 
Islet Isolation and Culture 
Pancreatic islets were obtained from 20-30 g male CD-1 mice as previously 
described.31 Briefly, mice were sacrificed by cervical dislocation, and collagenase P was 
injected into the pancreas through the main pancreatic duct. The pancreas was 
removed and incubated in 5 mL of collagenase solution at 37 °C for ~16 min. A Ficoll 
gradient was used to separate exocrine tissue from endocrine tissue, and islets were 
picked up by hand under a stereomicroscope. Islets with oblong to spherical shape, 
100-200 µm diameter and intact membrane (showing smooth surface) are selected for 
experiments. The islets are placed in RPMI-1640 cell culture media supplemented with 
10% fetal bovine serum, 100 unit mL-1 penicillin, and 100 µg mL-1 streptomycin at 37 °C, 
5% CO2, pH 7.4. Islets were used 2-5 days following isolation. 
Islets Pretreatments 
 To measure glucose sensitivity change, isolated islets were divided into control 
and experimental groups. Control islets were cultured overnight (16-18 h) in RPMI 1640 
media containing 11 mM glucose, whereas experimental islets were pretreated in RPMI 
1640 containing 2.8 mM, and 11 mM + 100 µM diazoxide (DMSO < 0.1 % by volume). 
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Results and Discussion 
Microfluidic Device and Operation Overview 
 The microfluidic chip is illustrated in Figure 2.1. This design allowed all buffers 
and reagents to be continuously perfused into the chip via syringe pumps and pressure-
driven flow to keep buffers pulled into the electrophoretic channels fresh. Suggested by 
previous study27, continuous perfusions keep immunoassay and electrophoresis stable 
for as long as 24 h. A single islet was placed in a chamber on the chip and continuously 
perfused with BSS, a physiological saline solution. 
Before loading the cells, standard operations to sterilize instruments contacting 
islets or perfusion buffer were performed. Glass vials, pipet tips and fused silica 
capillaries were autoclaved and kept in biosafety cabinet. Syringes, microfluidic 
channels and islet chamber were rinsed with ethanol and DI water before loaded with 
buffer. 
Calibration of Immunoassay and Limit of Detection of Insulin 
The insulin immunoassay calibration data (see an example in Figure 2.2) allow 
calculation of detection limits and evaluation of sensitivity. The detection limit was 0.5 
nM, calculated as the concentration required to give a B/F that was at least 3 standard 
deviations less than the B/F for 0 nM insulin. The assay was most sensitive in the range 
of 10-150 nM insulin, matching the majority of insulin concentrations that are detected 
from islets. The sensitivity range can be adjusted by changing the antibody and tracer 
concentrations.32 It is desired to have a 1:1 ratio at the low end of required dynamic 
range for best sensitivity. Sample electropherograms at low and high concentrations of 
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insulin are demonstrated in Figure 2.2. Calibration was performed daily to minimize 
variation. 
	  	
Figure 2.2. Sample electropherograms and a sample calibration curve. (A) Sample 
electropherograms at 0 nM and 200 nM insulin standards. Bound and free indicate 
Ab:Ag* complex and free Ag*, respectively. There are 2 free peaks because FITC-
insulin are mono- and double-labeled. We use the first free peak area for B/F 
calculation. B/F is approximately one at 0 nM insulin. (B) A sample calibration curve. 
Error bars indicate ±1 standard deviation. The mean and standard deviation were 
calculated based on 10-15 electropherograms for each data point. 
Long-term Islet Culture 
To stably maintain islets on chip for 24 h is necessary for long-term monitoring. 
Previous work27 from our group suggested perfusion with fresh media is the key to keep 
islets healthy. Moreover, we found it is also important to keep the inner-environment of 
the islet chamber sterile. Islet morphology is a straightforward indicator of the viability of 
the islets in their microfluidic environment. We confirmed this observation by comparing 
islets cultured in sterile and unsterile cell chamber and used islet morphology as an 
indicator. As illustrated in Figure 2.3, one islet cultured in unsterile cell chamber 
suffered disrupted membrane and did not appear healthy while the one in sterile 
A B 
	 45	
chamber remained intact membrane. Fraction of healthily cultured islets increased from 
1/7 to 27/33 after taking the steps of sterilization. 
	
Figure 2.3. Islet morphology comparison. Two islets were placed in 11 mM glucose 
in a 360 μm diameter cell chamber on a heated long-term microfluidic device for 24 
h. One culture condition was sterilized with ethanol prior to experiments as 
described in the experimental section and the other was not. Both were perfused 
with 11 mM glucose. The unsterile one appeared disrupted membrane and the cells 
were leaking out from the core, thus did not appear healthy. In contrast, the other 
one kept in sterile condition remained intact islet capsule. 
Long-term Insulin Secretion Monitoring 
 To illustrate the potential of the system for long-term cell monitoring, we used it to 
record insulin secretion from single islets treated with 3 to 11 mM step changed glucose 
with up to 25 h stability. 7 islets were successfully monitored for 12 h or more, although 
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clogs in the chip caused quicker failure in other attempts. The average insulin secretion 
cut at 12 h is illustrated in Figure 2.4. It shows an initial burst of 1st phase insulin 
secretion followed by a lower plateau of 2nd phase. Calibrations were performed at the 
beginning and end of experiments. 
 
	
Figure 2.4. Average long-term insulin secretion. Average of insulin secretion from 
7 islets (A) and an enlarged view of the 1st hour insulin secretion (B). The error 
bars indicate SEM of the mean. Time of glucose change from 3 mM to 11 mM is 
indicated by a red arrow. 
To continuously assess stability performance of long-term running of 
electrophoresis, it is necessary to periodically calibrate the immunoassay while keeping 
the cells under stable perfusion. To achieve that with the islet present, an independent 
channel parallel with the islets was implemented for calibration. During long-term 




standard and a SPDT controlled by a program periodically connected it to ground 
allowing sampling from this channel. 
 A single islet that was successfully monitored for 25 h as illustrated in Figure 2.5, 
combining automatic calibration every 5 h. The calibration was checked periodically by 
measuring the B/F of 100 nM insulin. The single point calibrations are also shown in 
Figure 2.5, confirming that the calibration of the immunoassay system was stable over 
the course of the long-term experiment. Several representative insulin secretion 
dynamics are enlarged in Figure 2.5 for better view. For this particular islet, it secreted 
insulin with ~6 min period of strong oscillatory burst between approximately 10-15 h. 
The islet did not immediately begin to oscillate after the initial burst, which is a 
characteristic of in vitro perfused mouse islets that has been suggested by previous 
studies.33,34 However, the oscillations afterwards and the transition between oscillatory 






Figure 2.5. (A) 25 h islet insulin secretion. An example of 25 h insulin release from 
a single islet treated with 3 to 11 mM glucose step change. It was perfused with 
BSS and glucose at 0.6 µL min-1.  (B)-(D) Several enlarged view of insulin secretion 
dynamics are shown. (E) Calibrations were performed every 5 h automatically with 
a SPDT relay to measure any drift over the course of 24 h period. 
Glucose Gradient Characterization 
 Fluid mixing is the most important performance consideration for the gradient 
generator. To assist in determining the mixing, a COMSOL model was developed to 
simulate the mixing process. For easy demonstration, low and high concentrations were 
set as 0 mM and 1 mM. A line scan was set at the outlet of the mixing channel to track 
the average concentration change. Screenshot of mixing status of 6, 10 and 16 s and 




the concentration at the mixing outlet is illustrated in Figure 2.6. We also attempted 
different flow rate combination to achieve different concentrations. 
	
Figure 2.6. (A) A COMSOL model simulating on-chip mixing. In this specific set-up, 
flow rates of both arms of the Tee were set at 0.3 µL min-1 with concentrations of 0 
and 1 mM. Snapshots of the process of mixing is demonstrated. (B) Average 
concentration at the outlet of the mixing channel is monitored. A 1:1 mixing 
reaches the concentration of 0.5 mM. 
 To validate the capability of the system to generate gradients, different profiles 
were programmed in the software for testing. Fluorescein was used to mimic glucose 
(or other stimulus) and measured at the end of the mixing channel. Low and high 
concentrations of fluorescein were loaded on 2 syringe pumps and perfused with 
different flow rates. The 2 profiles pre-setup in the program were illustrated in Figure 
2.7. The delay time was 5 s and the rise time from 10% to 90% of intensity difference 
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between 2 concentrations was 10 s. The stable and smooth step and gradual change 
validated that glucose ramp can be generated with this system. 
	
Figure 2.7. Programmed on-chip glucose changes with pumps mimicked by 
fluorescein. (A) Program controlled step changes from 0 nM to 2 nM fluorescein. 
(B) Continuous changing the syringe pumps flow rates slightly each minute to 
allow mixed concentration gradually increases in the total 22 min time. 
Glucose Sensitivity Measurements with Glucose Ramp 
 This device was applied for glucose sensitivity studies. Islets pretreated with 3 
mM, 11 mM and 11 mM + DZ for 16-18 h were assessed in response to ramping 
glucose from 1 mM to 24 mM in 1 mM increments (rate, 1 mM/min). As illustrated in 
Figure 2.8, islets exposed to 11G overnight responded to glucose ramps by rapidly 
secreting insulin once a threshold near 7 mM was reached and slowly subsiding. 
Abruptly reducing glucose at the end of the ramp resulted in a slow decline of secretion 
and subsequently stepping glucose up to 25 mM produced a secondary peak (not 
shown in Figure 2.8). Islets exposed overnight to 11G/Dz had earlier insulin release in 
the ramp, indicating a left shift; while overnight treatment with 3 mM glucose caused a 
right shift and less insulin output. The bar graphs in Figure 2.8 quantify the threshold 
glucose shift with each condition. 
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 β-cell threshold glucose concentration is one of the most important parameters to 
assess their sensitivity to glucose.28 It is straightforward to reflect the lowest 
concentration of glucose to evoke insulin secretion. In our study, we have found that 
inhibiting insulin secretion with Dz left shifted (enhanced) glucose sensitivity and 
glucose concentration lower than 11 mM right shifted (reduced) it. In the collaborative 
work35, measurements of Ca2+ and electrical oscillation with islets treated with the same 
condition had coincident results, suggesting insulin and low concentration of glucose 
have opposing actions on the islet glucose sensitivity. 
	
Figure 2.8. Insulin secretory dynamics in the 3 treatment groups. (A) Secretion from 
mouse islets chronically exposed to 11G (solid black line), 3mM glucose (dashed 
black line), or 11G + Dz (red line). The leftmost ordinate depicts average insulin 
secretion rate, in pg/min, of 7-9 single islets in each condition, whereas the wedge 
shown at upper right corresponds to ramped glucose levels. (B) Threshold glucose 
values of islets cultured overnight in 3mM, 11mM, or 11G + Dz. ***, P < .001; **, P 
< .01. 
Conclusion 
 We have demonstrated a versatile microfluidic platform capable of long-term cell 
culture and chemical monitoring, combining automatic glucose (or other stimulus) 
gradient control and calibration. It has been demonstrated useful for several 
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applications to study insulin secretion dynamics from pancreatic islets, including 
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A Microfluidic System to Study Cell-cell Interaction 
Introduction  
Cell-cell interactions are vital to normal operation of cells.1–3 Indeed, it is well-
known that isolated cells in culture may differ in function from the same cells in vivo due 
to the loss of normal cellular milieu that is comprised of structure and secretions from 
other cell types. Studying cells in vivo however can be challenging experimentally and 
ethically. Furthermore, it is difficult to manipulate the interaction of specific cells in vivo. 
In vitro models that mimic the in vivo microenvironment better than isolated cells are 
effective alternatives. A simple method to study cell-cell interaction is to co-culture 2 cell 
types in both sides of a transwell4 or a single compartment5. Although useful, these 
methods have unrealistic volume-to-cell ratio and lack fluid dynamics and mass 
transport that are part of the in vivo environment. They also do not lend themselves to 
dynamic control over the cellular environment and integration with chemical 
measurements. In this work, we describe a microfluidic system that allows secretions 
from one cell type to interact with a second while using an integrated immunoassay to 
monitor protein release from the target cells. The system is used to investigate 
adipocyte effects on insulin secretion from islet cells. 
Microfluidics has emerged as a powerful tool to create in vitro cell conditions that 
better mimic an in vivo environment. These tools are often called “organs-on-a-chip” or 
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“human-on-a-chip” to emphasize the creation of an in vivo like environment in the 
controlled confines of a microfluidic device. These systems were first developed to 
mimic in vivo pharmacokinetics and pharmacodynamics (PK/PD) on a chip.3,6,7 The 
devices have interconnected compartments containing lung, liver, fat and other tissues 
in a circulatory system so that drugs introduced to the cells are metabolized similar to in 
vivo. Subsequent improvements include creation of 3-dimensional environments and 
long-term culture.8–11 The concept has grown beyond drug metabolism so that now 
microfluidics has been further used for other types of cell-cell interaction such as studies 
on adhesion of platelets to endothelial tissue12 and neovascularlization13. These 
systems have revealed many advantages such as precise control of cell culture 
environment, consumption of small amounts of tissue and media, and high-
throughput.7–14 In these “organ-on-chip” studies, the experimental output was typically a 
microscopic inspection of the cells. For the drug metabolism studies, the resulting 
metabolites were measured by collecting products and analyzing resulting samples off-
line. 
Microfluidics also enables integration of cellular manipulation and cellular 
analysis. One approach has been to combine flow cytometry15,16, cell sorting17,18 and 
cell lysis followed by extraction of intracellular contents19,20 and in vitro cellular 
measurements (see reference 21 for a review of recent developments). Another 
approach has been to measure cell function by monitoring chemical secretions from 
cells incubated on microfluidic devices.22–29 In our own work in this area we have 
coupled chips to mass spectrometry providing a powerful way to identify and quantify 
multiple secretions from cells. More relevant to the current work, we have also 
	 57	
demonstrated the potential of monitoring the dynamics of insulin secretion from single 
islets of Langerhans with up to 8 s temporal resolution by perfusing cells and analyzing 
the perfusate using rapid, on-line electrophoretic immunoassay.30 
Islets are 75-200 µm diameter spheroid cell clusters located in the pancreas that 
contain 2000-4000 cells each, 70-80% of which are insulin secreting β-cells.31 β-cells 
are stimulated to secrete insulin at elevated blood glucose concentration32, which is 
crucial for maintaining glucose homeostasis33. Insulin secretion has complex dynamics. 
In vitro step increases in glucose concentration (typically from 3 mM to 11 mM) usually 
result in an initial burst (first phase) and oscillations with periods of 3-5 min (second 
phase) insulin secretions.34 
Many studies of insulin secretion from islets in vitro have been reported with the 
goal of better understanding the mechanism of secretion. It is known that the 
extracellular environment in vivo contains many factors that modulate insulin secretion. 
One cell type that is of interest for its effects on islet cells is the adipocyte. Adipocytes 
are fat-storing cells that secrete glycerol and non-esterified fatty acids (NEFAs) as a 
result of the catabolism of triglycerides through lipolysis.35 NEFAs have been shown to 
have bimodal effects on insulin secretion so that short term they enhance secretion but 
with chronic exposure they may suppress insulin secretion, suggesting a possible 
mechanism for dysfunctional insulin secretion in diabetes. Adipocytes also produce 
adipokines (a group of hormones and cytokines) which have been shown to affect 
pancreatic β-cells.33,36 
It is well-known that obesity is a risk factor for diabetes which is characterized by 
impaired insulin secretion. This observation suggests the possibility that adipocytes 
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secretions might play a role in degrading islet cell function. Previous studies have 
suggested that dysregulation of several adipokines’ secretion observed in obesity may 
promote insulin resistance, change insulin sensitivity and regulate insulin secretion (see 
reference 37 for a review), representing a potential pathophysiological link between 
obesity and type 2 diabetes. Investigations of adipocyte secretory products on insulin 
secretions have mostly relied on exposing islets to isolated components, such as 
NEFAs or individual adipokines; although, some studies38 have focused on adipokine 
interactions. In this study, we demonstrate with a microfluidic system that adipocytes 
have impact on insulin secretion that cannot be explained by NEFA results alone. The 
results show that better mimicking the in vivo microenvironment, where the β-cell is 
exposed to full range of adipokines, provides a more integrated perspective to study 
adipokines’ effects on the β-cell. 
Experimental Section 
Chemicals and reagents 
Cell culture reagents, Amplex UltraRed Reagent, and Hank’s buffered salt 
solution (HBSS) (Cat.No. 14175) were purchased from Life Technologies (Carlsbad, 
CA). Monoclonal antibody (Ab) to human insulin was purchased from Meridian Life 
Science (Memphis, TN). Tricine, electrophoresis grade was obtained from MP 
Biomedicals (Aurora, OH). Collagenase P was obtained from Roche Diagnostic. 
Fluorescein isothiocyanate-labeled insulin (FITC-insulin) Tween 20, 
ethylenediaminetetraacetic acid (EDTA), insulin and fatty acid free bovine serum 
albumin (BSA) were obtained from Sigma-Aldrich (St. Louis, MO). The fatty acid assay 
reagents and standard solution were purchased in a kit of HR Series NEFA-HR (2), 
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from Wako Chemicals USA, Inc. (Richmond, VA). All other chemicals were from Fisher 
(Pittsburgh, PA). All solutions were prepared with Milli-Q (Millipore, Bedford, MA) 18 MΩ 
deionized water and filtered with 0.2 µm nylon syringe filters (Fisher) before using. 
Stock antibody solution was stored at 4 °C in the manufacturer provided phosphate 
buffer saline. Stock FITC-insulin was diluted to 166 µM in immunoassay reagent buffer 
and stored at -20 °C. 
Balance salt solution (BSS) contained 125 mM NaCl, 5.9 mM KCl, 1.2 mM 
MgCl2, 2.4 mM CaCl2, 25 mM Tricine, and 0.7 mg mL-1 BSA. Immunoassay reagent 
buffer contained 60 mM NaCl, 1 mM EDTA, 20 mM tricine, 0.1% (w/v) Tween 20 and 
0.7 mg mL-1 BSA. Electrophoresis buffer was 20 mM NaCl and 150 mM tricine. All 
buffers were adjusted to pH 7.4. 
Glass Microfluidic Chip Fabrication and Preparation 
The microfluidic devices were fabricated using a method previously 
described.26,39 Briefly, the device consisted of 2 etched glass wafers: a bottom wafer for 
the bottom portion of the adipocyte chamber and a top wafer for the fluidic channels and 
the top portion of the adipocyte cell chamber. 1 mm thick Borofloat photomask blanks 
(3.8 cm X 10.2 cm) coated with a 120 nm layer of chrome and AZ1518 positive 
photoresist (Telic Company, Valencia, CA) are exposed to UV light for 6 s through a 
patterned photomask (Fineline Imaging Inc., Colorado Springs, CO). The exposed 
photomasks were developed in AZ 726 MIF developer (Clariant Corp., SummerVille, 
NJ) and the exposed chrome was developed in CEP-200 chrome etchant (Microchrome 
Technologies, Inc., San Jose, CA). The exposed glass was etched in 17:96:7 (v/v/v) 
HNO3/HF/H2O for 57 min to create 250 µm deep cell chamber on the bottom wafer and 
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17:24:79 (v/v/v) HNO3/HF/H2O for 25 min to create 25 µm deep channels on the top 
wafer. Fluidic access holes and top portion of the adipocyte cell chamber were drilled in 
the top wafer with 360 µm diameter (Kyocera Tycom, Costa Mesa, CA) and 9.5 mm 
diameter (Starlite Industries, Rosemont PA) drilling bits, respectively. The remaining 
photoresist was removed with acetone and the remaining chrome was removed with the 
CEP-200 chrome etchant. Glass wafers were washed for 20 min in piranha solution 
(3:1, v/v, H2SO4/H2O2) and then heated RCA solution (5:1:1, v/v/v, H2O/NH4/H2O2) for 
40 min. Caution!: piranha solution is aggressive and explosive. Never mix piranha 
waste with solvents. Check the safety precautions before using it. The wafers were 
rinsed with water, aligned and annealed at 610 °C for 8 h. Reservoirs and access ports 
(IDEX Health and Science, Oak Harbor, WA) were glued to the device over drilled 
access holes with epoxy glue.  
Polydimethylsiloxane (PDMS) slice fabrication 
All of the PDMS used in the chip fabrication was RTV-615 (Curbell plastics, 
Livonia, MI) and had base to curing agent ratio of 10:1. A mold was made by milling 9.1 
mm diameter and 0.8 mm depth wells on plastic at desired positions. A 2 mm layer of 
PDMS was poured over the mold and heated to 80 °C for at least 30 min before been 
peeled away from the mold. It was cut to appropriate shape to use afterwards. 
Computational modeling 
Perfusion of the cell chambers was modeled using COMSOL Muitiphysics 
(COMSOL, Inc., Burlington, MA). The “laminar flow” and transport of diluted species” 
models were used to monitor the flow split and theoretical temporal resolution. All 
simulations assumed water perfusion through the chip, with a density of 998 kg m-3 and 
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a viscosity of 1.002 × 10 -3 Pa ·s’ (20 °C). The diffusion coefficient used for oleic acid 
was 5.26 × 10-10 m2 s-1. 40 The adipocyte and islet chamber were modeled separately 
due to size difference to reduce computation times with different mesh accuracy. Both 
cell chambers were modeled in a 3D geometry. The adipocyte chamber had dimensions 
of 9.5 mm diameter × 1 mm with a 9.1 mm diameter × 0.8 mm cylinder removed from 
top to mimic the PDMS plug on the cover piece. The islet chamber had dimensions of 
0.36 mm diameter × 1 mm. The inlet and outlet channels for the cell chamber were 
modeled in 2D with the shallow channel set to 36 μm tall. The cell chamber inlet flow 
rate was set at 0.3 µL min-1.  
Microfluidic Chip Operation 
The layout of the microfluidic chip is shown in Figure 3.1. All solutions were daily 
filtered from a stock solution to prevent introduction of particulates to the chip or 
degradation. The chip was conditioned prior to experiments by flowing 0.1 M NaOH 
through the channels, followed by deionized water and experimental solutions.  
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Figure 3.1. Microfluidic chip layout. In the top layer (A), microfluidic channels are 
indicated by solid lines; Electrical connections are indicated by dotted lines. 
Circles indicate perfusion inlets and squares indicate reservoirs that are sampled 
by electroosmotic flow (EOF). At the adipocyte chamber portion, 2 holes with 
diameter of 9.5 mm were drilled. On the bottom layer (B), 2 circles with diameter of 





Figure 3.2. Side view of adipocytes and islet perfusion culture. Adipocytes and islet 
were loaded into cell chambers and perfused with pressure-driven flow, after which 
the fluid flowed into a 100 μL fluidic reservoir. The adipocyte chambers were sealed 
with a piece of PDMS slice. Solution with insulin from the chamber was sampled 
by EOF through the sampling channel at a rate of approximately 2 nL min−1. 
Cell culture 
Adipocytes and islets were perfused with BSS containing glucose at 0.6 µL min-1. 
For islet experiments, a single islet was placed in the grounded islet reservoir. The 
adipocytes chamber and PDMS cover piece were rinsed with 70% ethanol and dust was 
removed with Scotch tape. To load adipocytes, 2 coverslips with ~190,000 attached 
3T3-L1 adipocytes were removed from the culture dish with sterile tweezers and placed 
in the lower cell chamber. Cells per coverslip were roughly estimated by the fraction of 
the plate area occupied by the coverslip on the culture plate times the total number of 
cells, assuming an even distribution of cells. Total number of cells was estimated from 
the number of seeded preadipocytes (measured by hemocytometer) and the replication 
rate during differentiation. About 50 µL of buffer was added to prevent trapping bubbles 
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during sealing. Blank coverslips were applied for control experiments. The PDMS slide 
was pressed with the rear end of a tweezer to make a conformal contact. 
A compression frame to enclose the adipocyte portion was built in-house from 2 
sheets of acrylic plastic. Holes were drilled through both sheets along the outer edge to 
allow screws to pass through to tighten the frame. Figure 3.4 shows the assembled 
chip in the compression frame. 
	
Figure 3.3. Workflow of Experiments. During step 1, islets were co-cultured with 
adipocytes for 3 h without chemical monitoring; during step 2, perfusion from 
adipocytes was stopped and glucose was delivered from the side channel to 
stimulate the islet. 
Step 1 Perfusion co-culture 
for 3 h 
Step 2 
Glucose stimulation with 3 




Figure 3.4. The assembled chip in compression frame with only the cell culture 
portion is shown. Red food dye was perfused into the channels for better 
visualization. 
Perfusion and Chemical Monitoring 
The workflow of experiments is illustrated in Figure 3.3. During co-culture, BSS 
buffer was pumped onto the chip through adipocytes and islets, via fused-silica 
capillaries pumped by external syringe pumps (Chemyx, Stafford, TX). During chemical 
monitoring, perfusion through adipocytes was stopped and buffer was perfused directly 
to islets through a side channel. Besides islet reservoir, to provide fresh buffer to all the 
other reservoirs, appropriate solutions were continuously pump onto the chip via fused-
silica capillaries inserted into vials in a reservoir pressurized to 12 psi with helium.  
Negative high voltage (-6 kV) was applied at the waste reservoir of the device. 
With all the other reservoir grounded, Solutions containing insulin secreted by islet and 
100 nM FITC-insulin were mixed and reacted competitively with 50 nM Ab on a heated 
reaction channel. Both FITC-insulin and Ab were dissolved in immunoassay reagent 
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buffer. Electrophoresis buffer was pumped into gate and waste reservoirs. The gate 
reservoir is connected to ground via a high voltage relay. Injection is performed by 
opening the relay as described elsewhere.41 When the relay is opened, sample is 
allowed to load onto the separation channel. The gate is then returned to ground and 
separation is performed. Another sample can be loaded after the previous separation is 
completed. Sample injection time is 0.5 s applied at 7.5 s intervals. Laser-induced 
fluorescence detection occurs 1 cm from the injection cross. Each separation results in 
a FITC-insulin bound to antibody (B) peak followed by a free FITC-insulin (F) peak. 
Concentration of insulin is quantified by comparing B/F peak areas ratios of each 
electrophoregrams to a calibration curve. 
Instruments and LIF Detection 
LIF detection was performed with a Zeiss Axiovert 35 M inverted microscope 
equipped with a Photon Technology International 814 photometer (Birmingham, NJ). 
The 488 nm Excitation light of a 20 mW optically pumped semiconductor Sapphire laser 
(Coherent, Santa Clara, CA) is directed onto a 500 nm long-pass dichroic mirror and 
through a 40×, 0.6 numerical aperture, long working distance objective (Carl Zeiss, Inc., 
Thornwood, NY). After passing through the dichroic mirror, the emission light is further 
filtered through a 530 ± 30 nm band-pass filter. The fluorescence emission is further 
spatially filtered by an iris diaphragm on the photometer. Instrument control and data 
collection are performed using LabVIEW software written in house (National 
Instruments, Austin, TX). High-throughput analysis of collected electropherograms is 
performed using Cutter software.42 
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Adipocyte culture 
8 mm diameter glass coverslips (Warner Instruments, Hamden, CT) were 
sterilized in 70% ethanol for at least 1 h and were then dried in a sterile culture hood. 
Three to four coverslips were placed in each 35 mm petri dish using sterile tweezers 
prior to seeding preadipocytes. Murine 3T3-L1 preadipocytes were seeded into the 35 
mm dishes (200,000 cells per dish), maintained in Dulbecco’s modified Eagle’s medium 
(Cat. No. 11965-092, Life Technologies) with 8% v/v bovine calf serum (Denville 
Scientific, South Plainfield, NJ), 100 units mL-1 penicillin, 100 µg/mL streptomycin, 2 mM 
L-glutamine, and 1 mM sodium pyruvate and were stored in an incubator with 10 % 
CO2. Two days after the cells became confluent, differentiation (adipogenesis) was 
induced by adding 500 µM methylisobutylxanthine, 1 µM dexamethasone, and 5 µg/mL 
insulin. Medium was replaced with adipogenic medium was the same as the 
preadipocyte medium except that 10 % fetal bovine serum replaced the bovine calf 
serum two days post-differentiation. Every 2 days following, culture medium was 
refreshed with adipogenic medium that did not contain insulin. Adipocytes were matured 
to at least 14 days post-induction before on-chip experiments. 
Islet Isolation and Culture 
Pancreatic islets were obtained from 20-30 g male CD-1 mice as previously 
described.43 Briefly, mice were sacrificed by cervical dislocation, and collagenase P was 
injected into the pancreas through the main pancreatic duct. The pancreas was 
removed and incubated in 5 mL of collagenase solution at 37 °C for ~16 min. A Ficoll 
gradient was used to separate exocrine tissue from endocrine tissue, and islets were 
picked up by hand under a stereomicroscope. Islets with oblong to spherical shape, 
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100-200 µm diameter and intact membrane (showing smooth surface) are selected for 
experiments. The islets are placed in RPMI-1640 (Thermo Fisher 11875, 11 mM 
glucose) cell culture media supplemented with 10% fetal bovine serum, 100 unit mL-1 
penicillin, and 100 µg mL-1 streptomycin at 37 °C, 5% CO2, pH 7.4. Islets were used 2-5 
days following isolation. 
Off-line NEFA Enzyme Assays 
 NEFAs concentration was determined by collecting perfusates on chip and 
performing enzyme assays on a multi-plate reader (Perkin Elmer Fusion) using a 
method described previously.25,44 Briefly, the fatty acid reagents were reconstituted per 
manufacturer’s instructions to create Color Reagent A (CR-A) and Color Reagent B 
(CR-B). 20 μL perfusate was mixed with 200 μL CR-A and incubated at 37 ˚C for 10 
min. 9.3 μL of reconstituted Amplex UltraRed Reagent (33 M prior to mixing) and 400 
μL CR-B were then added and incubated at 37 ˚C for another 10 min. The mixture was 
transferred into 96 well plates and measured in multi-plate reader. The fluorescent 
reagent was excited by 535 nm light and emitted 620 nm fluorescence. 
Results and Discussion 
Microfluidic Device and Operation Overview 
The microfluidic chip developed for cell-cell interaction integrated with 
electrophoresis-based insulin secretion monitoring is illustrated in Figure 3.1. A side 
view of the cell culture portion is illustrated in Figure 3.2. This chip design builds on 
previous work aimed at measuring insulin secretion from islets26,27 and NEFAs from 
adipocytes24,25. This prior work identified important principles of microfluidic cell culture 
such as minimizing the difficulty of loading cells into the chip, prevention of shear stress 
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on the cells during perfusion, and simple regeneration of chips which are used in this 
work. Our goal in this work was to produce a chip that exposes islets to adipocytes 
producing physiological concentrations of NEFA and observe the effect on glucose 
stimulated insulin secretion as a model of cell-cell interaction with integrated analysis.  
The chip contains 3 cell chambers, 2 to hold adipocytes and 1 to hold a single 
islet. 2 coverslips containing adipocytes were placed at the bottom of the cell chambers, 
which were sealed by placing a PDMS “slice” in the open top chamber.  The adipocyte 
chamber portion was pressed to make a conformal contact with a compression frame. 
This procedure allowed easy loading and re-use of a chip. Single islets were pipetted 
into the open islet chamber. Leaving the islet chamber open to atmosphere (Figure 3.2) 
allowed: 1) easy loading and unloading of the chamber; 2) perfusate from the 
adipocytes to flow out the top of the chamber without causing high flow into the 
electrophoresis channel; and 3) the potential for placing sensors or electrophysiological 
probes in the islet for other studies.  
During operation, the adipocytes were perfused with BSS, a physiological saline 
solution at 0.3 µL min-1. The perfusate passed into the islet chamber so that islets were 
exposed to adipocyte secretions. After perfusion for a desired period, the adipocyte flow 
was stopped and glucose solutions were perfused to the islet chamber (Figure 3.3, 
Step 2) to record glucose stimulated insulin secretion. 
At 0.6 µL min-1 perfusion system rapidly replaced the solution in the islet chamber 
(approximately 100 nL volume) in a few seconds. The rapid wash-out allows high 
temporal resolution monitoring of insulin secretion from the islet. The islet chamber was 
continuously sampled at 2 nL min-1 by electroosmotic flow generated by applied voltage 
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from the chamber to the exit of the electrophoresis system (Figure 3.3, Step 2). The 
resulting sample stream was mixed with immunoassay reagents (Ab and FITC-insulin) 
in the reaction channel. This stream was injected every 8 s onto the electrophoresis 
channel where the bound and free FITC-insulin were separated (sample 
electropherograms shown in Figure 3.5). Using a calibration curve, these data enabled 
determination of insulin concentrations and secretion rates. To improve reliability of the 
continuous operation of the electrophoresis chip, a pressure-driven flow was used to 
replenish buffers and reagents into the chip. Continuous electrolysis in buffer reservoirs 
will degrade buffers, so that perfusion of buffers is effective to maintain long-term 
electrophoresis stability28. With these precautions, electrophoresis was stable for 3 h of 
measurement, although longer times are possible.28 Keeping buffer refreshed also 
obviated the need to condition the chip for every electrophoresis measurement, which 
can be tedious and prone to fail after assembling the adipocyte culture portion. 
	
Figure 3.5. Sample electropherograms and a sample calibration curve.		(A) Sample 
electropherograms at 0 nM and 200 nM insulin standards. Bound and free indicate 
Ab:Ag* complex and free Ag*, respectively. There are 2 free peaks because FITC-
insulin are mono- and double-labeled. We use the first free peak area for B/F 
calculation. B/F is approximately one at 0 nM insulin. (B) A sample calibration curve. 
Error bars indicate ±1 standard deviation. The mean and standard deviation were 
calculated based on 10-15 electropherograms for each data point. 
B A 
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Fluid dynamics of adipocyte and islet chamber 
Flow distribution and fluid dynamic response are important performance 
considerations for the chip. To assist in determining the flow conditions, several 
COMSOL models were developed. Adipocyte chamber and islet chamber flow profile, 
and cellular release were modeled separately (Figure 3.6). For simulations, the cell 
chamber inlet flow rate was set at 0.6 µL min-1. Measurements showed that the actual 
flow rate varied by less than 10% from this value. The volume of the adipocyte chamber 
was 40 µL, and the islet chamber was 0.1 µL based on calculations from the geometry 





Figure 3.6. COMSOL model of adipocyte chamber, islet chamber and cellular 
release. (A) Fluid distribution in adipocyte chamber; (B) Islet chamber and 
perfusion channel with single islet in it. The average concentration changes of 
the sphere (mimicking islet) sides facing and back to the perfusion channel were 
probed. The back side reaches 90% increase at 12 s. (C) and (D) Side view of the 
adipocyte chamber showing a simulation of the concentration flowing from the 
bottom of chamber assuming a constant release of chemicals from the cells 
below. The concentration reaching the outlet of the chamber had a 10-90 % rise 
time of 4 min. 
The flow through the adipocyte chamber and islet chamber are shown in Figure 
3.6A and B. A simulation of a chemical species injection into the adipocyte chamber is 
illustrated in Figure 3.6A, allowing visualization of the flow profile of the cell chamber. 
The flow across the cell chamber is uniformly distributed. Figure 3.6B illustrates 
chemical species simulation in the islet chamber. A sphere is located in the bottom of 






to the perfusion channel are probed to demonstrate uniform distribution of the fluid 
around the islet. 
Our goal was to expose islets to stable concentrations of adipocyte secretions. As 
shown in Figure 3.2, the adipocytes site in recessed chamber with flow passing over 
them. The recessed position protects the fragile cells from shear.24,45 As a result of the 
positions, secretions must diffuse into the flow path to be brought to the islets. Figure 
3.6C shows a simulation of the concentration flowing from the chamber assuming a 
constant release of chemicals from the cells below. The concentration reaching the 
outlet of the chamber had a 10-90 % rise time of 4 min as illustrated in Figure 3.6D. 
The model also shows that chemicals released from the adipocytes tend to stay near 
the bottom of the chamber as they flow downstream. This flow pattern favors rapid entry 
into the to the downstream channels towards the islet. 
Fatty acid concentration validation 
 The NEFA concentration reaching the islet will depend on the number of 
adipocytes present in the chip and mass transport as modeled above. Based on 
previous results, we estimated that 190,000 adipocytes would produce approximately 
80 μM NEFA at the islets. To confirm this expectation, fractions of perfusate were 
collected from the islet chamber and assayed for NEFA using a fluorescent enzyme 
assay. We also flowed standard concentrations of 50 µM and 100 µM palmitic acid 
through the chip to verify that suitable transport of known concentrations through the 
chip. As shown in Figure 3.7, standards gave the expected concentration indicating 
inconsequential NEFA loss through the chip. Adipocytes produced 80 μM putting it 
within the desired range.25 Suggested by previous investigation25, the concentration of 
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fatty acid produced by adipocytes highly relies on cell number and post induction day. 
Cells were counted and seeded to allow constant density batch by batch. They were 
applied for co-culture 14-20 days post-induction, when the NEFA secretion is stable. 
	
Figure 3.7. FFA concentration measured with off-line NEFA enzyme assay. Error 
bars indicate ± SEM. n = 3. 
Calibration of insulin immunoassay 
 The insulin immunoassay calibration data (see an example in Figure 3.5) allow 
calculation of detection limits and evaluation of sensitivity. The detection limit was 0.5 
nM, calculated as the concentration required to give a B/F that was at least 3 standard 
deviations less than the B/F for 0 nM insulin. The assay was most sensitive in the range 
of 10-150 nM insulin, matching the majority of insulin concentrations that are detected 
from islets. The sensitivity range can be adjusted by changing the antibody and tracer 
concentrations46 and it is desired to have a 1:1 ratio at the low end of required dynamic 
range for best sensitivity. Calibration was performed daily to minimize variation.  
Islet pretreatment, co-culture with adipocytes and insulin secretion monitoring 
We used the system to co-culture adipocytes and islets and record insulin 
secretion from single islets following 3 to 11 mM glucose step change. Results from 
adipocytes were compared to perfusion with 50 and 100 μM palmitic acid for the same 
	 75	
period as a positive control.  Palmitic acid was chosen because it is the most 
concentrated fatty acid in serum47,48, and it is widely used to study the effect of fatty acid 
on insulin secretion in lab. As shown in Figure 3.8, the islet chip records a classical 
peak of insulin secretion (first phase) followed by a lower rate (second phase) for all 
conditions. Pretreatment with palmitic acid potentiated the first phase of GSIS in a 
concentration dependent fashion (Figure 3.8 and Figure 3.9). Adipocytes, which 
produced 80 µM NEFA, had an even greater potentiation of secretion. The peak insulin 




Figure 3.8. Summary of insulin secretion stimulated with 3h palmitate (PA) 
pretreatment and adipocytes co-culture. Individual islets were isolated from 3-5 
individual mice in each condition. n = 5-19. 
	
 

















C o n tro l
1 0 0 µ M  P A
5 0 µ M  P A
A d ip . C o -c u ltu re
3  m M 1 1  m M  G lu c o s e
	 76	
	
Figure 3.9. Statistical analysis of 1st phase insulin secretion peak value (A) and 
average secretion rate (B). **** p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05. 
Second phase is typically low in mouse islets in vitro49,50, but sometimes 
oscillations were observed. We first compared the average 2nd phase insulin secretion 
rate after 1st phase peak (Figure 3.10) and found 100 μM palmitic acid and adipocytes 
stimulated more 2nd phase insulin secretion. Considering not all cells have 2nd phase, 
we further investigated the ratio of islets with active 2nd phase oscillations, and found 
10/19 (52.6 %), 9/14 (64.3%) and 9/12 (75.0%) islets had active oscillation in control, 
100 μM and adipocyte group, respectively (50 μM group is not included to compare with 
relatively smaller n-value). This data suggests that NEFAs and adipocytes may induce 
more 2nd phase insulin oscillation. Moreover, the 2nd phase oscillation frequency was 
counted, including all pulses between 1st phase peak till 30 min in each group (Figure 
3.10). It is worth noting that several islets co-cultured with adipocytes had a “rest period” 
between 1st and 2nd phase, lowering the frequency, although the intensity of 2nd phase 
oscillation was stronger (Figure 3.10). This phenomenon also suggests that prolonged 
monitoring would be meaningful to explore more on the effects of fatty acid and 
adipocytes on insulin secretion. Sample representative individual islets secretion traces 
are illustrated in Figure 3.11. 













































Figure 3.10. Statistical analysis of 2nd phase average insulin secretion rates (A) 
and oscillation frequency (B). ** p < 0.01; * p < 0.05. 
	
Figure 3.11. Representative insulin secretion from individual islets stimulated with 
3h palmitate (PA) pretreatment and adipocytes co-culture. 
These results suggest that the remarkable augmentation of secretion of insulin 
following exposure to adipocyte perfusate is due to more than NEFA. It may be due to 
either the mix of NEFAs that are released (although palmitic is a primary NEFA released 
from these cells51) or to other secretory products such as adipokines. Figure 3.8 
illustrates the averaged data from islets treated with different conditions. We observed 
enhanced 1st phase insulin secretion when islets were pretreated with 100 µM palmitic 
acid and halving the concentration of palmitic acid weakened the enhancement. 
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The enhanced insulin secretion with fatty acid pretreatment can be possibly 
explained with insulin releasable pool model.52 β-cells have a readily releasable pool 
(contributing to 1st phase) and reserve pool(s) (contributing to 2nd phase). When the 
cells are pretreated with high glucose/fatty acid or other stimulus for a period of time, 
they are primed to prepare more insulin at the readily releasable pool thus provide 
augmented 1st phase insulin secretion. The effects of fatty acid on mouse islets’ insulin 
secretion have been under debate for many years. Different attempts have been made 
by adding and removing fatty acid during low or high glucose and monitoring insulin and 
related hormone secretion53–56, or applying a glucose ramp to study glucose 
sensitivity57. Contradictory conclusions were drawn on effects of short-term fatty acid 
treatments on β-cell functions and the mechanism is still under debate. Our work first 
demonstrates 3 h pretreatment enhances insulin secretion even with relatively low FFA 
concentration, suggesting short-term fatty acid pretreatment is a positive regulator of 
insulin secretion. 
The 2 fold augmentation compared with equivalent fatty acid (100 µM) stimulated 
by adipocytes was even a little beyond our expectation. Although further validation may 
be required, the results here first demonstrates positive regulation of adipocytes, with 
potential amplified effects results from adipokines interplay. 
Moreover, we also measured intracellular Ca2+ concentration ([Ca2+]) of islets 
pretreated with 100 μM and blank buffer with a method described previously.58 The 
results (Figure 3.12) did not demonstrated significant difference between the 2 groups. 
Ca2+ influx caused by KATP channel closure has been widely known as the pace maker 
of insulin secretion32, while there are also KATP channel independent pathways exist.59,60  
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The lack of [Ca2+] alteration suggests that it not likely underlie the augmentation of 
insulin secretion, although further investigation is needed to confirm. The [Ca2+] data 
also suggests that insulin monitoring is meaningful to observe islets’ functions. 
	
Figure 3.12. Intracellular Ca2+ concentration of control islets and islets pretreated 
with 100 μM palmitic acid for 3 h. n = 7. 
Besides 1st phase, we also compared 2nd phase signal, and found co-cultured 
cells may have stronger 2nd phase oscillations. The short monitoring time limited our 
capability to find more evidence, which suggested longer-term measurement is 
necessary. Our group have extended the monitoring window to longer period of time28, 
where oscillations with different frequency and intensity were observed. In the future it 
would be desired to extend the monitoring time to study the 2nd phase, where ultradian 
(2 h rhythms)61 and circadian (24 h rhythms)62 were observed and deficiencies in them 
have been linked to type 2 diabetes. 
Meanwhile, the short-term positive regulation of adipocytes is potentially related 
to the pathogenesis of type 2 diabetes onset. Disregulated adipokine secretion may 
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cause insulin resistance and β-cell compensation and ultimately lead to β-cell 
failure.37,63 Longer-term co-culture would help us investigate more on this. 
Conclusion 
 We have developed a microfluidic chip capable of co-culture two cell types and 
chemical monitoring with capillary electrophoresis immunoassay. With this device we 
were able to study the effects of adipocytes on islets’ insulin secretion and found 
augmented insulin secretion after short-term treatment. This device keeps the capability 
of running long-term monitoring. With modifications, it may be used for further 
investigation of potential pathophysiological link between obesity and type 2 diabetes. 
The results illustrate the importance of using live cell interaction to modulatory effects of 
one cell upon the other. Retaining this design would also allow further studies on more 
complex studies such as comparing of short-term and long-term effects of adipocytes 
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Microchip for monitoring C-peptide-bearing Superfolder Green Fluorescent 
Protein (CpepSfGFP) secretion from living islets 
Introduction 
C-peptide is a short 31-amino-acid peptide connecting insulin A-chain and B-
chain in proinsulin, which is subsequently cleaved from the A-chain and B-chain 
producing mature insulin. A 1:1 mole ratio of C-peptide and insulin is stored in secretory 
granules of the β-cells and both are released during exocytosis. Therefore, a way to 
indirectly measure insulin secretion is to measure C-peptide levels.1 
A visual assessment of pancreatic insulin content would be a useful approach to 
study the loss of β-cell insulin content, which can be a possible cause of pancreatic 
exhaustion.2 However, imaging of insulin in the living animal or humans has not yet 
been achieved. A potential approach to imaging islets in vivo is to image a surrogate of 
insulin such as C peptide. Our collaborators have developed human proinsulin with C-
peptide-bearing Superfolder Green Fluorescent Protein (CpepSfGFP) as a potential 
dynamic reporter of insulin storage and secretion in situ. To use in vivo fluorescence 
imaging of CpepSfGFP in the pancreas to allow assessment of pancreatic islet insulin, it 
is necessary to validate the kinetics of the release of insulin and CpepSfGFP are 
identical. In vitro measurement with isolated single islets is a good approach to compare 
CpepSfGFP and insulin release. 
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In this chapter, we report on a microfluidic device to monitor C-peptide-bearing 
Superfolder Green Fluorescent Protein (CpepSfGFP) secretion from single islets. Its 
kinetics were compared with insulin secretion. 
Experimental Section 
 The microfluidic chip was modified for better performance, as illustrated in Figure 
4.1. The immunoassay channels were removed to increase sensitivity. Perfusion 
channels were also removed except the channel for islet perfusion. Chemicals and 
reagents, microfluidic chip fabrication and operation, detection, were the same as 
described in chapter 2 besides the following differences.  
 Islets isolation procedures were the same as chapter 2, except CpepSfGFP 
transgenic mice were used. Islets were preincubated for 1 h at 37 ˚C in Krebs-Ringer 
bicarbonate HEPES buffer (KRBH) (concentrations in mM: 4.7 KCl, 115 NaCl, 1.2 
KH2PO4,1.2 MgSO4, 2.56 CaCl2, 20 NaHCO3, and 16 HEPES; pH 7.2) supplemented 
with 2.8 mM glucose and 0.7% BSA, followed by 20 min of incubation in KRBH 
supplemented with 0.7% BSA in the presence of 25 mM glucose. The islets were also 
perfused with depolarizing KRBH solution (with 60 mM KCl) as positive control. 
Results and discussion 
Microfluidic Device Overview 
The microfluidic device was modified to measure CpepSfGFP secretion from 
islets as illustrated in Figure 4.1. Originally the experiments were attempted with the 
same microfluidic chip for insulin monitoring (Figure 2.1), while the immunoassay 
channels for FITC-insulin and insulin Ab were not used. However, we observed very 
weak peak intensity, possibly due to the low fluorescence quantum yield of CpepSfGFP, 
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and more importantly, due to low abundance of fluorescent labeled C-peptide. To avoid 
the fluorescent label affecting metabolism, only ~0.04 % of total islet C-peptide were 
labeled.  
Simply adding number of islets did not improve the intensity (for example loading 
3 islets did not provide a 3-fold signal enhancement). According to previous 
investigation, EOF tends to sample solution closest to the inlet of the electrophoretic 
channels. Although more islets were loaded, the peptide secreted from them may not be 
well sampled. 
 Another source of dilution is from the unused immunoassay channels, which 
were loaded with water. To avoid the dilution, in the new design, immunoassay 
channels were removed, the cell culture portion was also simplified to a single perfusion 
channel. Other perfusion channels were also removed because long-term monitoring is 
not needed in this application.  
	
Figure 4.1. Microfluidic chip for monitoring C-peptide secretion from single islet 
modified from the previous design. In comparison with the microfluidic chip for 
insulin monitoring (as illustrated in Figure 2.1), the parallel insulin standard 
channel, immunoassay channels were removed. All the other perfusion channels 
except for the islet chamber were also removed. 
Stably enhanced peak intensity was observed with these steps being taken and 
the modified chip was used for following experiments. The electropherograms of basal 
(2.8 mM glucose) and stimulated (25 mM) before and after the microchip modification 
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were illustrated in Figure 4.2, to demonstrate the signal enhancement achieved with the 
new chip. The results also demonstrated microfluidics techniques’ advantage in high 
sensitivity detection. 
	 	
Figure 4.2. Electropherograms of CpepSfGFP before modifying the microchip (left) 
and after (right). Representative traces of basal (2.8 mM glucose) and stimulated 
(25 mM glucose) conditions are demonstrated. Overt signal enhancement on both 
basal and stimulated conditions is observed with the new chip. 
C-peptide monitoring 
 C-peptide was monitored with this device as illustrated in Figure 4.3. The C-
peptide data is overlaid with insulin data, monitored with capillary electrophoresis 
immunoassay independently using islets isolated from CD-1 mice (as illustrated in 
chapter 2 and 3). The results here demonstrate that the kinetics of C-peptide secretion 







































Figure 4.3. Kinetics of transgenic CpepSfGFP and mouse insulin from isolated 
CpepSfGFP islets. Single islets were perfused at 3 mM glucose and then switched 
to 25 mM glucose (arrow at top). Single-islet secretion was measured by the release 
of GFP fluorescence (averaging of nine single-islet traces is shown by the dark 
solid line, with the lighter surrounding area showing the SEM on these 
measurements) and by competitive immunoassay for insulin (averaging of four 
single-islet traces shown in dashed line, with lighter surrounding area showing the 
SEM of these measurements), both at 8 s intervals throughout a 22.5-min time 
course. 
 The islets were also stimulated with 60 mM K+ as positive control. The results are 
demonstrated in Figure 4.4. Compared with glucose stimulated C-peptide, the profile 
secreted by K+ demonstrated slightly steeper response and transient duration. 
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Figure 4.4. Comparison of CpepSfGFP secretion stimulated by 60 mM K+ and 25 
mM glucose. Single islets were pretreated with KRBH supplied with 2.8 mM glucose 
for 1 h and then switched to 25 mM glucose or 60 mM K+ as indicated by the arrow. 
Error bars indicate ± SEM of 9 individual islets in both groups. 
 The above results show that CpepSfGFP and insulin have similar secretory 
responses as expected. This result supports the conclusion that monitoring CpepSfGFP 
is a useful surrogate for estimating insulin secretion. Our collaborators demonstrated the 
CpepSfGFP could be imaged in vivo at the pancreatic surface by fluorescence providing 
a way to assess pancreatic islet insulin content in vivo. In one application investigated in 
this work, when blood glucose reaches 15 mM, a small subset of islets showed rapid 
dispossession of a major fraction of their stored CpepSfGFP content, while most islets 
exhibit no demonstrable CpepSfGFP loss. It strongly suggested that there are “first 
responder” islets to an in vivo glycemic challenge.3 
 Although useful, the goal of this work was still to use CpepSfGFP to indicate insulin 
action, which made it necessary to prove the kinetics of CpepSfGFP release is identical 
to insulin. In vitro, single islet experiment is an excellent option to study such kinetics to 
prevent destructive interference of out of phase secretion from multiple islets in a large 
batch. Automatic high temporal resolved monitoring combining microchip electrophoresis 
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allowed easy recording of CpepSfGFP secretion profile using single islets, making the 
kinetics comparison more trustworthy. 
Conclusion 
 A microfluidic chip was developed to monitor fluorescent labeled peptides from 
single cells. This device was applied to monitor CpepSfGFP secretion from single islets 
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Investigation of the Role of X-Box Binding Protein 1 in Insulin Regulated 
Pancreatic α-cell Function 
Introduction 
It has been known that hyperglucagonemia caused by α-cell dysfunction is a 
feature of overt type 2 diabetes;1–3 but, the mechanism contributing to the 
hypersecretion is not fully understood. In addition to glucose4, previous studies found 
that insulin signaling in α-cells is critical to the regulation of glucagon secretion.5,6 
Impaired insulin signaling in α-cells leads to enhanced glucagon secretion.6,7 
Gradual loss of β-cell mass is a notable feature in type 2 diabetes patients, while 
α-cell’s mass is maintained relatively intact.8 Endoplasmic reticulum (ER) stress has 
been proposed as one factor contributing to reduced β-cell mass,9,10 but its role in α-cell 
biology is less known. Unfolded protein response (UPR) is an important process in 
development of ER stress. XBP1 is a transcription factor that plays a critical role in 
mediating the UPR. A recent study reported that β-cell specific XBP1-deficient mice 
exhibit β-cell dysfunction.11 
The goal of this collaborative work is to study the role of XBP1 in α-cells. In vivo 
(α-cell-specific XBP1 knockout mice) and in vitro (stable XBP1 knockdown and 
overexpression α-cell lines) models were prepared by collaborating labs. Ca2+ influx is 
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the trigger of exocytosis of hormones including insulin and glucagon. Cytoplasmic Ca2+ 
concentration ([Ca2+]) is an important parameter to assess the mechanism of 
dysregulation of glucagon secretion in the cells. In our work, XBP1 knockdown and 
overexpression α-cell lines’ [Ca2+] were measured in vitro and compared with the control 
groups. 
Fluorescence imaging is a promising and widely used technique for studying 
living cells. Intracellular Ca2+ measurements were revolutionized after the advent of cell-
permeant Fura-2, a Ca2+ sensitive fluorescent dye.12 Its excitation wavelength shifts 
from 380 nm to 340 nm upon Ca2+ binding, and the ratio of the integrated intensities of 
the fluorescence emission from 340 and 380 nm excitation allows for quantitation of 
intracellular Ca2+ following calibration. 
Conventional Ca2+ measurements are usually performed with cells affixed on a 
coverslip that is sealed into a chamber with approximately 3 mL volume. The chamber 
is perfused with a peristaltic pump. Although it has been applied in many applications, 
the drawbacks include large volume of media consumed and difficulty precisely 
controlling the cell culture environment. The microfluidic chip for Ca2+ imaging may allow 
rapid and precise introduction of fresh media to the cells. Several microfluidic devices 
have been implemented for intracellular [Ca2+] imaging recently.13–15 Two such 
microfluidic devices are illustrated in Figure 5.1. Our research group also have 
developed microfluidic devices for Ca2+ imaging in pancreas islets.16 
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Figure 5.1. Designs of microfluidic devices for Ca2+ imaging studies. (A) The 
schematic on the left depicts the cross-section view and experiment setup and the 
isometric view of the PDMS device is shown in the inserted image. The chip 
contains three layers: The bottom layer consists of an array of small circular wells 
(500 µm diameter) to immobilize the islets; a middle layer consists of the 7 mm 
diameter circular well; and the top layer of the microfluidic channels. (B) A PDMS 
microfluidic device reversibly sealed by positioning onto a glass coverslip. Cells 
were loaded into the Y-microfluidic channel and allowed 45 min to adhere before 
[Ca2+] monitoring. Arrows indicate perfusion direction. Reproduced from reference 
13 and 15. 
Here we demonstrate a polydimethylsiloxane (PDMS)/glass hybrid microfluidic 
chip for Ca2+ imaging applications. This device can accommodate a 5 × 5 mm square 
coverslip loaded with cells, and allows continuous perfusion over them during 
measurement. Excess buffer is removed from the top of the cell chamber and the 
temperature is well controlled. The reusable device is easy to fabricate and maintain, 





Chemical and Reagents 
Cell culture reagents were purchased from Life Technologies (Carlsbad, CA). 
Human insulin, dimethyl sulfoxide (DMSO), and hexamethyldisilazane (HMDS) were 
obtained from Sigma (St. Louis, MO). All other chemicals were from Fisher (Pittsburgh, 
PA). Krebs Ringer buffer (KRB) contained (in mM): 118 NaCl, 5.4 KCl, 2.4 CaCl2, 1.2 
MgSO4, 1.2 KH2PO4, 20 HEPES and 0.5/25 glucose. 
Microfluidic Chip Fabrication 
 The double layer PDMS portion of the device was fabricated with soft lithography 
techniques as previously described.17–19 All the PDMS used in the chip fabrication was 
RTV-615 (Curbell Plastics, Livonia, MI) and had a base to curing agent ratio of 10:1. To 
fabricate the PDMS layer with microfluidic channels, HMDS was spun on a 3-in. silicon 
wafer (University Wafer, Boston, MA) to facilitate photoresist adhesion. SU-8 2075 
photoresist (MicroChem, Newton, MA) was spun onto the wafer to create a 60 μm layer 
and was patterned using a dark-field photomask with the design shown as the black 
lines in Figure 5.2. A thick layer (~5 mm) of PDMS was poured over the mold and 
heated to 80 °C for at least 30 min. A ~0.5-mm-thick layer was created by pouring 
PDMS over a blank silicon wafer. It was allowed to settle for 10 min before heated to 
80 °C for at least 30 min. Both layers were peeled away from the mold and bonded 
together using corona discharge and heated to 80 °C for 15 min. The bulk PDMS piece 
was cut to small pieces according to predefined rectangle shapes on the mold. The 
ends of the channels on each piece were exposed. A 7 mm diameter hole was punched 
at the center of each PDMS part as a cell chamber. Each piece was bonded to a glass 
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coverslip (Corning Cover glass, 50 x 24mm, Fisher) using corona discharge and heated 
again to 80 °C for 15 min. 
Microfluidic Chip Operation 
Fluidic connections were made by inserting 150 μm ID/ 360 μm OD fused silica 
capillaries (PolyMicro Technologies, Phoenix, AZ) to the beginning of the flow splitter 
from the open ends of the channels, as illustrated in Figure 5.2. The other ends of the 
capillaries were connected to perfusion buffer, pressurized with 30 psi of helium. Flow 
rate was adjusted to 40 μL min-1 on both sides to achieve a total flow rate of 80 μL min-1. 
Two high pressure chambers were connected to a 4-port valve (VICI Valco Instruments, 
Houston, TX) allowing switching buffer during experiments without stop of perfusion 






Figure 5.2. Open-top PDMS/glass microfluidic chip for Ca2+ imaging. (A) Design of 
the mold pattern for microfluidic channels. Solid lines indicate mold on a 3-in. 
silicon wafer (200 µm wide and 60 µm high). PDMS was poured on the mold and 
peeled away after dry, and cut to small rectangle pieces guided by the solid lines 
on mold. A dashed circle on the top-mid piece illustrates the location to punch the 
cell chamber. (B) Top view of a microfluidic chip. Dashed rectangle shape indicates 
the glass coverplate, where the PDMS piece is glued onto. Capillaries were inserted 
from the open end of the microfluidic channels on the side for fluidic access. The 
flow splitters are filled with red color food dye. (C) Side view of the microfluidic 
chip. The dashed lines represent the interfaces between layers bonded by corona 
discharge. Capillaries introduce buffer to the inlet of the flow splitters to allow 
uniform fluid profile in the cell chamber. Excess buffer is constantly removed on 



























Cell Culture  
 Glucagon-secreting αTC6 cells were obtained from our collaborator and cultured 
as reported previously.20 They were normally maintained in Corning 75 cm2 cell culture 
flasks (Fisher). For Ca2+ imaging experiments, glass coverslips were cut to 5 ´ 5 mm 
squares. The coverslips were sterilized in 70% ethanol for at least 1 h and then dried in 
a sterile culture hood. Three to four coverslips were placed in each 35-mm petri dishes 
using sterile tweezers prior to seeding the cells. Cells were detached from the culture 
flasks with trypsin (0.25%, Life Technologies) and seeded to the petri dishes. 
Experiments were performed using 80-90% confluent cells. Cells were cultured in 
Dulbecco’s modified Eagle’s media containing 25mM glucose (DMEM, Life 
Technologies) supplemented with 10% fetal bovine serum (Life Technologies) and 100 
unites mL-1 Penicillin/Streptomycin (Life Technologies) and stored in an incubator with 
5 % CO2. 
Computational Modeling 
Perfusion of the cell chambers was modeled using COMSOL Muitiphysics 
(COMSOL, Inc., Burlington, MA). The “laminar flow” and transport of diluted species 
models were used to monitor the flow split and theoretical temporal resolution. All 
simulations assumed water perfusion through the chip, with a density of 998 kg m-3 and 
a viscosity of 1.002 × 10-3 Pa·s’ (20 °C). The cell chamber had dimensions of 7 mm 
diameter × 5 mm. The inlet channels for the cell chamber were modeled in 2D with the 
shallow channel set to 60 µm tall. The cell chamber inlet flow rate was set at 20 µL min-1 
on both sides. 
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Cell Preparation and Loading 
 Cell permeable Fura-2-acetoxymethyl ester (Fura-2 AM, Life Technologies) was 
dissolved in DMSO to create a stock concentration of 1 mM. Prior to loading on the 
chip, the coverslip with cells to be measured was transferred to DMEM culture media 
with 0.5 mM glucose and 2 µM Fura-2 for 45 min at 37 °C to load with dye. The 
microfluidic chip was rinsed with 70% ethanol, water and 0.5 mM glucose KRB 
sequentially, with 80 µL KRB added to the cell chamber and filled in the perfusion 
channels. The cells were gently rinsed with 0.5 mM glucose KRB in another petri dish 
and loaded on the chip. After connected to perfusion, the cells were perfused with 0.5 
mM glucose KRB for 10 min in dark (without measuring), before being treated with 
different conditions to measure [Ca2+]. KRB containing 30 mM KCl was applied at the 
end of each experiments as positive control. A temperature probe was inserted to the 
bottom of the chamber to keep tracking it. The temperature was maintained at 37 °C 
with heating strip adhering at the bottom of the chip. 
[Ca2+] Measurements 
 The chip was placed atop the stage of a Nikon Diaphot 300 microscope. Fura-2 
was alternately excited using a filter wheel with 340 and 380 nm light from a Xenon-arc 
lamp. The fluorescence emission from both excitation wavelengths was collected 
through a 510 ± 10 nm bandpass filter. Fluorescent images were collected at 1 Hz. 
Metamorph software was used to select single cells and integrate the intensity. [Ca2+] 
was determined by calculating the calculating the ratio of the emission at 340 and 380 




Figure 5.3. Screenshot of Ca2+ imaging in Metamorph software. The left 2 windows 
illustrate cells’ fluorescent images when excited by 340 and 380 nM light. The ratio 
of 340/380 is demonstrated in the 3rd window. Several cells were selected as the 
colorful circles illustrated in the 3rd window and the average ratios of the emission 
were tracked to calculate [Ca2+]. 
Statistical analysis 
 All data are expressed as mean ±SE and were analyzed with an unpaired two-
tailed Student t test or ANOVA as appropriate. Differences were considered significant 
at p < 0.05. 
Results and discussion 
Overview of microfluidic chip design 
 A reversibly sealed chip was applied for Ca2+ imaging previously in our group.22 
Cells were also loaded on the chip with a coverslip and sealed in the middle of 2 pieces 
of glass or PDMS for measurements. Although useful, that design was relatively hard to 
operate and prone to leakage. Moreover, the reversible design allows further use of 
perfusate at downstream for measurements or other application (e.g. co-culture as 
illustrated in chapter 3), while such applications are not needed in Ca2+ measurement. 
 The open-top PDMS/glass microfluidic chip (Figure 5.2) we designed in this work 
allowed easier cell loading and removal and chip operation than the reversibly sealed 
chip. It also avoids leakage. In this application, temperature of the media at the bottom 
340 nM     380 nM          340/380 
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of the cell chamber can be easily measured by inserting the temperature probe into the 
chamber. Other applications like electrochemistry measurements near cell can also be 
achieved if necessary. 
 In designing the microfluidic chip, the side-view illustrated in Figure 5.2 
demonstrated the 3-layer design: a thick layer with microfluidic channels, a blank thin 
layer and a glass coverslip supporting layer. The thin PDMS layer lifts the perfusion 
channels to allow fluid perfusing through the upper surface of the cells, preventing shear 
stress on the cells. The thin glass coverslip was applied as the supporting layer to fit the 
short working distance of the objective on the microscope. 13 microfluidic chips can be 
prepared once with one mold. 
 The 5 × 5 mm square coverslip helped better stabilize its position in the cell 
chamber. It matches the size of the 7 mm diameter cell chamber with 4 corners 
reaching the edge of the cell chamber. This snug fit prevented coverslip shifts during 
experiments. 
Chip characterization 
 To assist in determining the flow conditions, a COMSOL model was developed to 
simulate the cell chamber as illustrated in Figure 5.4. Two rectangular shapes were 
labeled near the bottom of the cell chamber to mimic different areas of the coverslip and 
the mean concentration of each are probed. 
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Figure 5.4. The cell chamber model built with COMSOL software and the mean 
concentration of different areas labeled near the bottom of the cell chamber. Flow 
rate from both ends were set at 20 μL min-1. Top of the cell chamber was set as the 
flow outlet. Time resolved intensity change is illustrated while position 1 and 2 (B) 
are associated with the 1 and 2 labeled in the model (A). 
Setting flow rate at 40 μL min-1, the model suggested that the parts closest to the 
perfusion channel had almost instant response and rise time, while closer to the center, 
the delay time was 26 s and rise time from 10% to 90% was 64 s. Food dye was applied 
to measure the delay time in the capillary when switching buffer, which was found to be 
8.7 ± 0.4 s. Food dye diffusion in the cell chamber is difficult to quantify, but the color 
was observed in the center of the chamber within 1 min. 
 In real cell culture experiments, only a small area of cells was aligned with the 
microscope objective for imaging (< 2 mm diameter circle). This characterization 
suggested using cells closer to the perfusion channel for faster response. Another way 
to evaluate rise and delay time was to 30 mM KCl to cells at the end of the experiment. 
High concentration KCl causes closure of KATP channel on the cell membrane to induce 
almost instant Ca2+ influx. The time from switching to 30 mM KCl to observance of K+ 
induced Ca2+ influx, including delay and rise time in both the perfusion capillary and the 




To access the mechanism of dysregulation of glucagon secretion in αTC6 cells, XBP1 
knockdown cells (αXBPKD), control cells for KD, XBP1 overexpressing cells (αXBPOE) 
and control for OE were perfused with glucose concentrations of 0.5 mM, 25 mM and 25 
mM + 100 nM insulin sequentially. Representative [Ca2+] profiles of each cell type are 
illustrated in Figure 5.5. Our results show that these cells displayed bursts or spikes of 
Ca2+ that were modulated by different conditions. The data were analyzed by counting 
the [Ca2+] spike per unit time as illustrated in previous reports.4 
 Consistent with previous reports4,23, [Ca2+] spikes in control cells were dampened 
by application of high glucose and insulin. A similar trend was evident in αXBPKD cells, 
but the response to high glucose and insulin was blunted compared with control cells. 
Meanwhile, the average [Ca2+] level in αXBPKD cells was not significantly different from 
control cells in all different glucose conditions and with 100 nM insulin. The basal [Ca2+] 
was significantly higher in αXBPOE cells compared with controls, although the [Ca2+] 
spikes were similar between them. Although increased glucagon secretion was found in 
αXBPKD cells in the collaborative work,24 the Ca2+ data suggest that [Ca2+] alterations 
are not likely to underlie the dysregulation of glucagon secretion in XBP1 deficient α-
cells. The lack of [Ca2+] alteration in αXBPKD cells helped to draw the conclusion that 
cAMP25 is a dominant second messenger in the regulation of glucagon secretion in α-
cells with other experiments performed. This conclusion is consistent with a previous 




Figure 5.5. Effects of altered XBP1 expression on [Ca2+] in aTC6 cells. The glucose 
(G) concentration was increased from 0.5 to 25 mM, and 100 nM human insulin was 
present as indicated. Representative traces are shown of single cells from control 
for KD (A), aXBPKD cell (B), control for OE (C), and aXBPOE cells (D). E: Basal [Ca2+] 
is shown for each group (n = 9-15 in each group). Data are expressed as means ± 
SEM. ***P < 0.0001. F: Quantification of frequency of spikes from each group (n = 




 We have demonstrated a PDMS/glass hybrid microchip for Ca2+ imaging studies. 
The device is convenient to fabricate, and the open-top design allows easy cell 
manipulation and chip operation. Compared to previous developments, it has small 
chamber volume allowing fast buffer changing. The recessed well also prevent shear 
stress applied on cells. It has been applied in a biological study to compare [Ca2+] 
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Summary and Future Directions 
Summary 
The overall goal of this work was to develop, refine, and apply new analytical 
instrumentation to study islets of Langerhans functions. Generally, we developed novel 
analytical tools and techniques to study insulin secretion, C-peptide secretion, and Ca2+ 
influx. The novel microfluidic device also allowed cell-cell interaction studies. Although 
islets, pancreatic α-cells and adipocytes are the model systems applied in this study, the 
developed analytical technology can be used to study other biological cells or systems. 
Microchip Electrophoresis for Chemical Gradient Generation and Long-term Operation 
The first tool was a microchip electrophoresis device for long-term cell culture 
and chemical monitoring, incorporating a method to automatically generate arbitrary 
glucose profiles and a method for automated calibration at defined times.  
Insulin secreted from the islets was measured at 5-10 s intervals by an 
electrophoretic competitive immunoassay. Every few hours, a single pole double throw 
(SPDT) relay controlled electrical connection moved from the islet reservoir to the 
parallel insulin standard reservoir, allowing the electrophoretic sampling of insulin 
standards while maintaining the islet under perfusion. 
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Single islets were perfused with different concentration of glucose. Processes of 
sampling of insulin secreted by the islet, insulin and FITC-insulin mixing and their 
competitively reacting with insulin antibody were achieved by electroosmotic flow (EOF). 
A high-voltage relay will control continuous injection of sample plug to the separation 
channel, where free FITC-insulin and FITC-insulin bound to antibody were separated. 
The integrated system can perform 14,000 electrophoresis assays in 24 h and 
automatically control culture condition, thus allowing continuous monitoring of insulin 
under well-controlled conditions. 
To control glucose, the system incorporates two independent syringe pumps 
loaded with low and high concentration glucose. Flow rates of both were controlled by a 
home-made LabView program. By mixing 2 syringe pumps’ contents at different flow 
rates through a tee fabricated on the electrophoresis chip, arbitrary glucose gradients 
can be generated. The glucose gradient was applied to measure glucose sensitivity of 
islets exposed to various glucose concentrations overnight in vitro. The concentrations 
of glucose that able to trigger measureable insulin secretion were progressively reduced 
by 3 mM, 11 mM or 11 mM + Diazoxide (an insulin secretion inhibition drug) overnight 
treatment, suggesting an increase in glucose sensitivity. 
A Microchip Electrophoresis System to Study Cell-cell Interactions 
A microchip electrophoresis device was developed to study the impact of 
adipocytes on islet insulin secretion by co-culture both cells. During co-culture, buffer 
was pumped onto the chip through adipocytes and islets. Palmitic acid with 
concentration similar to the NEFAs secreted by adipocytes were used to treat islets as 
positive controls. During chemical monitoring, perfusion through adipocytes was 
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stopped and buffer was perfused directly to islets through a side channel. Insulin 
concentration was measured with the same manner as illustrated with the long-term 
chip. 
Our work demonstrated that 3 h pretreatment with 80 µM palmitic acid enhances 
insulin secretion, suggesting short-term FFA treatment is a positive regulator of insulin 
secretion. The 2-fold augmentation compared with equivalent fatty acid (80 µM) 
stimulated by adipocytes may be due to either the mix of NEFAs that are released or to 
other secretory products such as adipokines. Although further validation may be 
required, the results here demonstrates the first positive regulation of short-term 
adipocytes pretreatment on insulin secretion, with potential amplified effects results from 
adipokines interplay. 
Microchip for monitoring C-peptide-bearing Superfolder Green Fluorescent Protein 
(CpepSfGFP) Secretion from Living Islets 
A microfluidic chip was developed to measure low concentration fluorescent 
labeled peptides. Modifications were made on the previously developed immunoassay 
chip by removing immunoassay channels to prevent dilution. The chip was applied to 
measure islet C-peptide-bearing Superfolder Green Fluorescent Protein (CpepSfGFP) 
secretion. To avoid the fluorescent label affecting metabolism, only ~0.04 % of total C-
peptide were labeled, resulting in a very low signal intensity of C-peptide. With the 
modification applied, signal of CpepSfGFP was detected. Its intensity also increased 
when the islets were stimulated with high glucose. By comparing this results with insulin 
secretion, it was concluded that CpepSfGFP has identical in vitro kinetics with insulin 
secretion. 
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Investigation of the Role of X-Box Binding Protein 1 in Insulin Regulated Pancreatic α-
cell Function with Ca2+ influx measurements 
A polydimethylsiloxane (PDMS)/glass hybrid microfluidic chip for Ca2+ imaging 
applications was developed. This device can accommodate a 5 × 5 mm square 
coverslip loaded with cells, and allows continuous perfusion over them during 
measurement. Excess buffer is removed from the top of the cell chamber and the 
temperature is well controlled. The reusable device is easy to fabricate and maintain, 
and allows easy cell loading and removing. 
The chip was applied to measure Ca2+ influx to study the role of XBP1 in 
pancreatic α-cell. XBP1 is a transcription factor that plays a critical role in mediating the 
Unfolded protein response (UPR). XBP1 deficiency in pancreatic β-cell has been 
reported causing β-cell dysfunction. Stable XBP1 knockdown and overexpression α-cell 
lines’ [Ca2+] were measured in vitro. Significant [Ca2+] level alterations were observed, 
suggesting that [Ca2+] alterations are not likely to underlie the dysregulation of glucagon 
secretion in XBP1 deficient α-cells. 
Future Directions 
Several advancements can be made to the devices studied and developed in this 
dissertation. For the long-term microchip, our goal is to develop a system combining 
automatic control of culture condition and long-term stability. The system can be 
improved in 2 aspects. To keep the cells healthy on chip for longer time, the perfusion 
media can be optimized to supply more nutrients. Improvements can also be applied to 
increase the stability of long-term electrophoresis operation. 
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For the cell-cell interaction studies, based on existing results, several directions 
can be further investigated including comparing short-term and long-term treatments, 
and applying inflamed adipocytes for co-culture, which are likely to impair islets’ insulin 
function. The microchip can also be further developed to monitor multiple islets in 
parallel to improve throughput. 
Improvement of Perfusion of Islets on Long-term Electrophoresis Chip 
Although the islets studied in Chapter 2 of this paper exhibited intact shape and 
normal insulin secretion dynamics for more than 24 h, the islets were perfused with BSS 
buffer, which only contains necessary salts and glucose. It is more appropriate and 
desired to supply more nutrients allowing more optimized in vitro environment for the 
islets and potentially longer-term culture. Commercial cell culture medias such as RPMI 
1640 or DMEM are not applicable for the reason as discussed previously1, primarily due 
to the incompatibility between phosphate buffer system and relatively high concentration 
Ca2+ demand for insulin secretion. Compensating Ca2+ to a final 2.4 mM concentration 
in RPMI 1640 was attempted, but caused sedimentation in the media. Adding BSA or 
fetal bovine serum (FBS) to phosphate-free buffer (like Balanced salt solution) was 
another approach attempted to provide nutrients, however, protein can be attracted to 
the wall of the capillary. Existence of too much protein prevents EOF, making it 
incompatible with electrophoresis. Investigation done in this work showed 2% BSA 
already affected the EOF and caused broadened electropherograms. Although such 
buffer may not be appropriate for electrophoresis, they are still good candidates for on-
chip cell culture. A potential practice is to apply protein rich buffer during cell culture 
(pretreatment), rinse and perform electrophoresis measurements with buffers containing 
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less protein. Besides proteins, to provide multi-vitamin and amino acid for the cells by 
adding them to the BSS buffer can also be an important portion to supply more 
nutrients. These methods require further investigation and optimization to achieve better 
performance. 
Improvement of Long-term Stability of Electrophoresis 
To better mimic in vivo glucose profile is our goal with the microchip 
electrophoresis. As illustrated in Figure 1.7, blood glucose profiles in animals usually 
fluctuate. Such profiles can be mimicked by the programmable gradient generator, and 
it has been applied to study glucose sensitivity of islets. However, to investigate long-
term insulin studies with more physiologically relevant glucose patterns, the more 
challenging portion is to maintain the electrophoresis stable for more than 24 h. 
Although such time span has been achieved in this dissertation, the success rate was 
not sufficient to consistently replicate the experiments allowing biological conclusions 
being drawn. The main challenge to overcome, at least as perceived in my work, is 
clogs in the microfluidic channels.  
The two main sources of clogs are broken tissue parts leaking into channels and 
buffer salts sedimentation. They were alleviated by improving cell culture and 
preventing salts sedimentation, as discussed in chapter 2. However, although clogs 
were well contained for short-term experiments (3-5 h), they still frequently happened 
after 12 h electrophoresis operating. 
As discussed in chapter 2, all electrophoresis buffers were continuously perfused 
to keep fresh, when buffer vials were stored in room temperature for 24 h. Assuming 
such condition may lead to buffer degradation, measures were taken by storing 
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perfusion buffer in ice bath or changing fresh buffer preserved in fridge every few hours. 
However, these steps did not show significant improvement on electrophoresis stability. 
Another hypothesis is gradual sedimentation still builds up in channel due to 
electrolysis, despite the buffers are continuously refreshed. Mixing buffers with different 
recipe in such small channel can make the situation more severe. One way to alleviate 
effects of electrolysis is to apply high voltage with less amount of time. As illustrated in  
Figure 6.1, the constant high voltage at waste reservoir can be replaced by a relay, 
switching between high voltage and ground. During a long-term monitoring, by 
programming the position of the added relay, electrophoresis can be turned on and off 
performed intermittently (e.g. every 30 min). Although some secretion information is not 
recorded, it may worth the trade off if monitoring time can be extended. 
	
Figure 6.1. Diagram of the microchip electrophoresis. Modified application on 
waste channel is marked in red. Switching waste reservoir to ground stops the 
















Compare Short-term and Long-term Fatty Acid Pretreatment and Co-culture On-chip 
Although it has been known that short-term NEFA treatment is a positive 
regulator of insulin secretion, most short-term studies were performed by administrating 
NEFAs during glucose treatment and measure insulin secretion immediately.2–4 One 
study5 pretreated islets with 0.5 mM palmitic acid at 4 mM glucose for ~30 min, and then 
stimulated them with 8 mM glucose. Palmitic acid showed a clear 2 fold potentiation of 
GSIS in that study. Another study6 pretreated islets with 0.5 mM palmitic acid for 1 h but 
did not observe significant GSIS augmentation. The results in this dissertation 
demonstrated that short-term pretreatment of fatty acid enhances insulin secretion even 
with relatively low fatty acid concentration, suggesting short-term fatty acid pretreatment 
is a positive regulator of insulin secretion. 
NEFA modulation of GSIS in islets, also termed as “lipid signaling”, can signal 
directly via a free fatty acid receptor, GPR40.7–10 It is also known that intracellular 
metabolism of NEFAs resulting in the synthesis of lipid signaling molecules such as 
long-chain acyl-CoA (LC-CoA) and diacylglycerol (DAG), which are very important in 
NEFA’s role in modulating GSIS (see reference 11 for a review). In this dissertation 
work, 1 h and 2 h pretreatments with palmitic acid were also attempted, but produced 
inconsistent results, while 3 h pretreatment consistently enhanced GSIS. It is likely an 
indication that NEFA’s effect on insulin secretion is time dependent.12,13 For a future 
direction, experiments can be applied to expose islets to different length of time, and 
compare the effects on insulin secretion. More than that, since metabolism is a factor of 
NEFA modulation in b-cells, it is also interesting to measure islet metabolomics. Our 
group previously have developed method using LC-MS for such applications with  b-cell 
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lines.14,15 Modifications on the method were also made to apply to islets, which can be 
used in applications of this work in the future. 
Meanwhile, previous evidence suggested that chronic (~48 h) exposure of fatty 
acid resulted in impaired insulin secretion.16 Such effects are illustrated in Figure 6.2. 
Saturated NEFAs have been known to reduce insulin biosynthesis and secretion and 
induce b-cell apoptosis.11 Monitoring GSIS and metabolomics of islets pretreated with 
NEFAs for long-term (more than 48 h) may provide us better understanding of how this 
process happens. The results can also be compared with short-term treatments (less 
than 6 h). 
Similar experiments can also be performed with adipocytes co-culture. Co-culture 
of adipocytes and islets cannot reproduce a completed in vivo environment without 
interacting with other tissue cells, however, it may potentially reveal the direct effects of 
adipocytes on islets. The receptors of several adipokines have been found on b-cells 
(see reference 17 and 18 for a review). Also, a lot of type 2 diabetes patients have been 
obese for a long time before hyperglycemia and dyslipidemia19. It is possible that 
adipose tissue already leads to b-cell dysfunction, even ahead of high level of blood 
glucose and NEFAs. In this dissertation, we demonstrated short-term adipocytes co-
culture augments GSIS. It would be interesting in the future to investigate long-term 
adipocyte-islet co-culture. It is possible that the short-term enhancement may cause b-
cell compensation, which ultimately lead to b-cell failure and defected insulin secretion. 
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Figure 6.2. GSIS from islets chronically exposed to fatty acids. Islets were cultured 
for 48 h with 0.125 mM indicated fatty acid. Chronic exposure to palmitate and 
oleate increased basal insulin release and impaired GSIS (with 27 mM glucose). 
Chart recreated with data from reference 16. 
Compare Inflamed and Normal Adipocytes’ Effects on Insulin Functions 
Secretion of NEFAs and several adipokines levels were found abnormal during 
obesity. TNF-a-an inflammatory cytokine and the first molecular link between 
inflammation and obesity-was found overexpressed in the adipose tissue of rodent 
obesity models20,21 and obese humans22–24. With more inflammatory mediators being 
found exhibit patterns similar to TNF-a during obesity, transcriptional profiling studies 
verified that inflammatory and stress-response genes are the most regulated in adipose 
tissue of obese animals25–27 (A list of alterations of many of these genes and other 
adipokines secretion can be found in reference 28). Disregulation of the inflammatory 
cytokines and adipokines may cause insulin resistance and β-cell compensation and 
ultimately lead to β-cell failure18,28,29, but their roles in directly regulating insulin 
secretion were less studied and discussed. As a future direction, it would be interesting 
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to apply inflamed adipocytes directly on islets and study their effects on insulin 
secretion.  
Inflammation in 3T3-L1 adipocytes can be induced with treatment of TNF-a as 
described previously.30 Non-TNF-a treated adipocytes can be used as a negative 
control. Another approach is to directly use inflamed adipocytes from obese individuals. 
Although primary adipocytes are challenging to be cultured for more than 24 h, the 
experiments can be designed to use the adipocytes immediately after isolation. A 
microfluidic device was reported using primary adipocytes immediately after isolation 
and has been applied to measure adiponectin secretion.31 Using the media cultured with 
adipocytes to treat islets is another approach. These studies can be used for further 
investigation of potential pathophysiological link between obesity and type 2 diabetes. 
Qualification and quantification of NEFAs and adipokines secretion from adipocytes 
Palmitic acid was applied as positive control of adipocytes in this dissertation. 
Although it is one of the major fatty acids secreted by adipocytes, a mixture of major 
NEFAs secreted by adipocytes can be used as a more representative positive 
control.32,33 Characterizations of NEFAs and adipokines are also important directions, 
particularly to measure their alteration in inflamed adipocytes secretions. The Kennedy 
group recently developed methods coupling chips to mass spectrometry, providing a 
powerful way to identify and quantify multiple secretions from adipocytes.34 Figure 6.3 
illustrated full scan analysis of mass spectrum of on-line elution profile from 3T3-L1 
adipocytes. This experiment can be applied to characterize fatty acid secretion. The 
perfusate during co-culture can be collected and introduced to the on-line solid-phase 




Figure 6.3. On-line elution profile from 3T3-L1 adipocytes. Full scan analysis of 
m/z ranging from 200 to 320 performed on a QQQ-MS. Adipocytes loaded in the 
cell chamber were stimulated with isoproterenol/forskolin. An on-line solid phase 
extraction bed was applied to load fatty acid samples and subsequently washed. 
Sample was eluted to the MS. Peaks are labeled with the NEFAs that associate 
with the appropriate m/z. Reproduced from Reference 34. 
Adipokines were not identified or quantified in this dissertation work, although 
such measurements have been proceeded with 3T3-L1 adipocytes in previous 
studies.35 Figure 6.4 demonstrated protein expression of a few major adipokines. In the 
future, techniques like SDS-PAGE/LC-tandem MS36,37 and gene expression analysis30 
can be applied to better assess adipokines secretion. 
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Figure 6.4. The expression of adipocyte-secreted factors in 3T3-L1 cells. Leptin, 
adiponectin and resistin are expressed in differentiated 3T3-L1 adipocytes and in 
fat tissues from mouse epididymis fat pad, but not in undifferentiated 3T3-L1 
preadipocytes. TNF-a was only weakly detected in fat tissues. Reproduced from 
Reference 35. 
Microfludic Device for Co-culture Studies in Parallel 
 The Kennedy group previously developed a microfluidic electrophoresis device 
for high-throughput, automated, online monitoring of insulin secretion from as many as 
15 single islets in parallel38, which has been described in chapter 1. Higher throughput 
analysis by parallel measurements results in reduced time and cost. Furthermore, for 
the co-culture studies, parallel measurements allow better control of islets culture 
conditions. To be more specific, islets with the same time after isolation can be placed 
on nearby locations on chip, while co-cultured with adipocytes, fatty acid standards or 
blank coverslip. Figure 6.5 illustrated a microchip designed for 2 co-culture groups on 
the same chip. This chip was attempted for a few times but several challenges were not 
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well resolved yet. The adipocytes chambers portion was designed to be sealed with 2 
sheets of acrylic plastic. Because this chip is wide, applying screws only on both ends 
easily bended the plastic sheets, leading to leakage in the adipocyte chambers in the 
middle. A better design is needed to seal the adipocyte chambers. The experimental 
protocol to maintain 2 islets is also tedious and prone to error, which may need further 
simplifying. The Pretreatment step takes 3 h and measurements of insulin secretion 
takes 1 h. To keep both islets pretreated for the same length of time, after the 
adipocytes are loaded and primed on chip for 30-40 min, one islet is loaded first for 1 h 
before the other. They will be sequentially measured for insulin secretion afterwards. It 
would be desired to realize simultaneous measurement of multiple islets. A method to 
simultaneously measure multiple channels signal was previously developed by our 
group.39 It may also be useful to use a fluorescent camera for multichannel detection. 
These improvements can allow multiple islets pretreatment and insulin monitoring in 
parallel, thus increase throughput. 
	
Figure 6.5. A microchip design culturing 2 islets. 2 co-culture groups are 
designed on the same chip while sharing the same insulin measurement part. 
During experiment, one islet is loaded first while the other is loaded in 1 h. 
Afterwards, insulin secretion are monitored in sequence. 
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Conclusion 
To summarize, several microfluidic devices have been designed and developed 
in this dissertation for different applications, including unattended insulin secretion 
monitoring combining gradient generation, cell-cell interaction studies on chip, direct 
monitoring of fluorescent peptides, and [Ca2+]i measurements. The future directions 
include several aspects, focused on improvement of the stability of the long-term MCE 
system, more complex biological applications with the co-culture chip to better 
understand the effects of NEFAs and adipocytes on islets’ insulin function, and 
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